ï‚·ï‚·
ï‚·Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the 
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D 
Vaccine Administered Concomitantly and Sequentially in Healthy Subjects 
Aged 18 to 60 years in Non-Endemic Country(ies) 
Study ID: [REMOVED]
Protocol Approve Date: 28 November 2018
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from view 
with a black/blue  bar) 
to protect either personally identifiable information ([COMPANY_003]) or company confidential 
information (CCI)
. 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
TITLE PAGE  
PROTOCOL  
A Randomized, Observer -Blind, Placebo -Controlled, Phase 3 Trial to Investigate the 
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever  
YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects 
Aged  18 to 60 years in Non -Endemic Country(ies)  
Immunogenicity and Safety of TDV Administered with a Yellow Fever Vaccine in Adults  
Sponsor:  [COMPANY_005] Vaccines, Inc.  
[ADDRESS_219243],  
Cambridge, MA [ZIP_CODE],  
[LOCATION_003]  
Trial Identifier:  DEN -305 
IND Number:  [ADDRESS_219244] Number:  Not Applicable  
Vaccine Name:  ï‚·Investigational vaccine: [COMPANY_005]â€™s tetravalent dengue vaccine
candidate (TDV) comprised of a molecularly characterized,
attenuated dengue serotype 2 strain (TDV -2), a dengue serotypes 2/1
chimeric strain (TDV -1), a dengue serotypes 2/3 chimeric strain
(TDV -3), and a dengue serotypes 2/4 chimeric strain (TDV -4)
ï‚·Licensed live yellow fever (YF -17D) vaccine
ï‚·Place bo: saline solution
Date:  28 November  2018  
Version:  Version 4.0 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
7DNHGDÂ¶V7HWUDYDOHQW'HQJXH9DFFLQH&DQGLGDWH
7ULDO1R'(1 3DJHRI
3URWRFRO9HUVLRQ 1RYHPEHU
$'0,1,675$7,9(,1)25 0$7,21 
&RQWDFWV 
7DEOHD&RQWDFW,QIRUPDWLRQ 
,VVXH &RQWDFW
6HULRXVDGYHUVHHYHQWDQGSUHJQDQF\
UHSRUWLQJ
0HGLFDO0RQLWRU
PHGLFDODGYLFHRQFRQGXFWRISURWRFRORUFRPSRXQG
(PHUJHQF\PHGLFDOFRQWDFWLQIRUPDWLRQZLOOEHSURYLGHGWRWKH
VLWH
5HVSRQVLEOH0HGLFDO2IILFHU
FDUULHVRYHUDOOUHVSRQVLELOLW\IRUWKHFRQGXFWRIWKHWULDO
(PHUJHQF\PHGLFDOFRQWDFWLQIRUPDWLRQZLOOEHSURYLGHGWRWKH
VLWH[COMPANY_003]
QZLOOEHSQZLOOEa
WLQIRUPDLQIRUPctble Terms of UseT
anapplicable
7DNHGDÂ¶V7HWUDYDOHQW'HQJXH9DFFLQH&DQGLGDWH
7ULDO1R'(1 3DJHRI
3URWRFRO9HUVLRQ 1RYHPEHU
$SSURYDO 
5(35(6(17$7,9(62)7$.('$ 
7KLVWULDOZLOOEHFRQGXFWHGZLW KWKHKLJKHVWUHVSHFWIRUWKHL QGLYLGXDOSDUWLFLSDQWVLQDFFRUGDQFH
ZLWKWKHUHTXLUHPHQWVRIWKLVFOLQLFDO WULDOSURWRFRODQGDOVRLQDFFRUGDQFHZLWKWKHIROORZLQJ 
x7KHHWKLFDOSULQFLSOHVWKDWKDYH WKHLURULJLQLQWKH'HFODUDWLR QRI+HOVLQNL
x,QWHUQDWLRQDO&RXQFLOIRU+DUPRQL] DWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU3KDUPDFHXWLFDOVIRU
+XPDQ8VH(*RRG&OLQLFDO3UD FWLFH&RQVROLGDWHG*XLGHOLQH
x$OODSSOLFDEOHODZVDQGUHJXODWLRQVLQFOXGLQJEXWQRWOLPLWHG WRWKRVHUHODWHGWRGDWDSULYDF\
DQGFOLQLFDOWULDOGLVFORVXUH
6,*1$785(6 
[COMPANY_003]UGDQFHGDQFH
RZLQJZLQJ
DUPDFHXUPDFH
RVHUHODWHVHUHO
of [COMPANY_005]: For non-commercial use only and subj
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219245] read and that I understand this protocol, the Investigatorâ€™s Brochure, and any 
other product information provided by [CONTACT_1034]. I agree to conduct this trial in accordance with 
the requirements of this protocol and also protect the rights, safety, privacy, and we ll-being of trial 
subjects in accordance with the following:  
ï‚· The ethical principles that have their origin in the Declaration of Helsinki.  
ï‚· International Council for Harmonization of Technical Requirements for Pharmaceuticals for 
Human Use, E6 Good Clinical  Practice: Consolidated Guideline.  
ï‚· All applicable laws and regulations, including, but not limited to those related to data privacy 
and clinical trial disclosure.  
ï‚· Regulatory requirements for reporting serious adverse events defined in Section  10.4 of this 
protocol.  
ï‚· Terms outlined in the Clinical Trial Site Agreement.  
ï‚· Appendix  A â€“ Responsibilities of the Investigator.  
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix  B of this protocol.  
  
Signature [CONTACT_185717] (print or type)   
  
Investigatorâ€™s Title   
  
Location of Facility (City, State)   
  
Location of Facility (Country)   
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 5 of 85 
Protocol Version 4.0  28 November 2018  
 
 1.3 Protocol Amendment Summary of Changes  
This document describes the changes in reference to the Protocol incorporating Amendment No.  2. 
The primary purpose of this amendment is to remove the planned Day 120 (Month 4 [M4]) interim 
analysis. Minor grammatical and editorial chang es are included for clarification purposes only. 
Full details on changes of text are given in Section 1.3.2 . 
1.3.1 Amendment History  
Date  Amendment Number  Amendment Type  Region  
30 May 2017  Initial Protocol  Not applicable  Global  
22 January 2018  1 Substantial  Global  
28 November 2018  2 Non-substantial  Global  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 6 of 85 
Protocol Version 4.0  28 November 2018  
 
 1.3.2 Summary of Changes  
Amendment to Protocol Version 3.0, 22 January 2018  
Rationale for the Amendment:  
The rationale for removing the planned Day 120 (M 4) interim analysis is that it is no longer 
required.  
The removal of this interim analysis has no impact on the final statistical analyses planned for 
this study, the scientific value of the study, the study conduct, or the safety of subjects enrolled.  
The administrative trial information has been updated and references list has been checked and 
updated as needed.  
Details of the changes are outlined below. In this section only (ie, not in the protocol body) all 
new text i s shown in bold italics and any redundant text is marked using strikethrough.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
7DNHGDÂ¶V7HWUDYDOHQW'HQJXH9DFFLQH&DQGLGDWH 
7ULDO1R'(1 3DJHRI
3URWRFRO9HUVLRQ 1RYHPEHU

6HFWLRQ 'HVFULSWLRQRIFKDQJH 
7LWOH
SDJH'DWH-DQXDU\ 1RYHPEHU 
9HUVLRQ
6HULRXVDGYHUVHHYHQWDQGSUHJQDQF\
UHSRUWLQJ
0HGLFDO0RQLWRU 
PHGLFDODGYLFHRQFRQGXFWRI
SURWRFRORUFRPSRXQG 
5HVSRQVLEOH0HGLFDO2IILFHU 
FDUULHVRYHUDOOUHVSRQVLELOLW\IRUWKH
FRQGXFWRIWKHWULDO 

5HSODFHG)LJXUHDDQG)LJXUH DLQ6HFWLRQVDQGUHVSH FWLYHO\ZLWK DKLJKHU
UHVROXWLRQ LPDJH[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Property of [COMPANY_005]5ke
ofnon-commercial use oOLW\IRUWLW\IRse
nerms of Useer
ttt to the applicable Ter
only and subject t
keda: For n
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 8 of 85 
Protocol Version 4.0  28 November 2018  
 
 Section  Description of change   
2.0; 
13.1.[ADDRESS_219246] completed Visit 4 (Day 120 [M4]). This analysis will be performed by a separate 
group of unblinded statisticians and programmers at a selected independent contract 
research organization (CRO) who will have access to individual vaccine assignm ent but 
will not be involved in subsequent trial conduct. The rest of the personnel involved in the 
conduct of the trial, including those at [COMPANY_005], the CRO, and the trial sites, will remain 
blinded to individual vaccine assignment until unblinding after t rial completion 
(database lock for data through the Day 360 [Month 12] follow -up visit). No 
modification to the trial will be made based on the results of this interim analysis. More 
details regarding the interim analysis will be provided in the SAP.  No in terim analyses 
are planned.  
6.1 Data collection will be by [CONTACT_185662] (eCRF) . Refer to Section 13.1.5  
for the planned interim analysis.  
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 9 of 85 
Protocol Version 4.0  28 November 2018  
 
 TABLE OF CONTENTS  
1.0 ADMINISTRATIVE INFOR MATION  ................................ ................................ .............. 2 
1.1 Contacts ................................ ................................ ................................ .......................... 2 
1.2 Approval  ................................ ................................ ................................ ........................ 3 
1.3 Protocol Ame ndment Summary of Changes ................................ ................................ ..5 
1.3.1  Amendment History  ................................ ................................ ................................ .5 
1.3.2  Summary of Changes  ................................ ................................ ............................... 6 
2.0 TRIAL SUMMARY  ................................ ................................ ................................ .......... 13 
2.1 Schedule of Trial Procedures  ................................ ................................ ....................... 23 
3.0 TRIAL REFERENCE INFO RMATION  ................................ ................................ ........... 26 
3.1 Trial -Related Responsibilities  ................................ ................................ ...................... 26 
3.2 Principal Investigator/Coordinating Investigator  ................................ ......................... [ADDRESS_219247]â€™s Expected Participation in the Entire Trial  ................................ 36 
6.4 Premature Termination or S uspension of Trial or Investigational Site  ....................... 37 
6.4.1  Criteria for Premature Termination or Suspension of the Trial  ............................. 37 
6.4.2  Criteria for Premature Termination or Suspension of Investigational Sites  .......... 37 
6.4.3  Procedures for Premature Termination or Suspension of the Trial or the 
Participation of Investigational Site(s) ................................ ................................ ...37 
7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL  OF SUBJECTS  ............... 38 
7.1 Inclusion Criteria  ................................ ................................ ................................ ......... 38 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 10 of 85 
Protocol Version 4.0  28 November 2018  
 
 7.2 Exclusion Criteria  ................................ ................................ ................................ ........ 38 
7.3 Criteria for Delay of Vaccination and/or Blood Sampling  ................................ .......... [ADDRESS_219248]  ................................ ........................ 41 
7.5 Criteria for Premature Discontinuation of Trial Vaccine Administration  ................... 42 
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT  ................................ ......................... 44 
8.1 Trial Vaccines and Materials  ................................ ................................ ....................... 44 
8.1.1  Dosage Form, Packaging, and Labeling  ................................ ................................ 44 
8.1.2  Storage  ................................ ................................ ................................ ................... 45 
8.1.3  Dose and Regimen  ................................ ................................ ................................ .45 
8.2 Trial Vaccine Assignment and Dispensing Procedures  ................................ ............... 46 
8.3 Randomization Code Creation and Storage  ................................ ................................ .46 
8.4 Trial Vaccine Blind Maintenance  ................................ ................................ ................ 47 
8.5 Unblinding Proce dure ................................ ................................ ................................ ..47 
8.6 Accountability and Destruction of Sponsor -Supplied Vaccine(s)  ............................... 47 
9.0 TRIAL PLAN  ................................ ................................ ................................ .................... 49 
9.1 Trial Proc edures  ................................ ................................ ................................ ........... 49 
9.1.1  Informed Consent Form  ................................ ................................ ......................... 49 
9.1.2  Demographics, Medical History and Prior Medications  ................................ ........ 49 
9.1.3  Documentation of Trial Entrance/Randomization  ................................ ................. [ADDRESS_219249] Trial Vaccine Compliance  ................................ ........................... 52 
9.3 Schedule of Observations and Procedures  ................................ ................................ ...52 
9.3.1  Pre-Vaccination Procedures (Day 1 [M0], Day 90 [M3], and Day 180 [M6])  ......52 
9.3.2  Vaccination Procedures (Day 1 [M0], Day 90 [M3], and Day 180 [M6])  ............ [ADDRESS_219250]-Vaccination Procedures (Day 1 [M0], Day 90 [M3], and Day 180 [M6])  ....53 
9.3.4  Clinic Visits after Vaccination (Day 30 [M1], Day 120 [M4], Day 210 [M7], 
and Day  360 [M12]) ................................ ................................ ............................... 55 
9.3.5  Final (End of Trial) Visit  ................................ ................................ ....................... [ADDRESS_219251]-Trial Care  ................................ ................................ ................................ .......56 
9.4 Biological Sample Retention and Destruction  ................................ ............................. 56 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219252]-Trial Events  ................................ ................................ ................................ ....64 
11.0  TRIAL -SPECIFIC REQUI REMENT(S)  ................................ ................................ ........... [ADDRESS_219253] Retention  ................................ ................................ ................................ ......... 66 
13.0  STATISTICAL METHODS  ................................ ................................ .............................. 68 
13.1  Statistical and Analytical Plans  ................................ ................................ .................... 68 
13.1.1  Analysis Sets  ................................ ................................ ................................ .......... 68 
13.1.2  Analysis of Demographics and Other Baseline Characteristics  ............................ 68 
13.1.3  Immunogenicity Analysis  ................................ ................................ ...................... 68 
13.1.4  Safety Analysis  ................................ ................................ ................................ ......69 
13.1.5  Interim Analysis and Criteria for Early Termination  ................................ ............. 70 
13.2  Determination of Sample Size  ................................ ................................ ..................... 70 
14.0  QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ................. 72 
14.1  Trial -Site Monitoring Visits  ................................ ................................ ......................... 72 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219254] and/or Independent Ethics Committee Approval  ............ [ADDRESS_219255] Informed Consent Form  ................................ .................. 82 
Appendix  D Serology Plan  ................................ ................................ ................................ ......... 85 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 13 of 85 
Protocol Version 4.0  28 November 2018  
 
 2.0 TRIAL SUMMARY  
Name [CONTACT_790]:  
[COMPANY_005] Vaccines, Inc.  
[ADDRESS_219256] Name:  
[CONTACT_185718] (TDV)  
Trial Title:  A Randomized, Observer -Blind, Placebo -Controlled Phase 3 Trial to Investigate the Immunogenicity and 
Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF -17D Vaccine Administered Concomitantly 
and Sequentially in Healthy Subjects A ged 18 to 60 years in Non -Endemic Country(ies)  
IND No.:  [ADDRESS_219257] No.: Not Applicable  
Trial Identifier:  DEN -305 Phase:  3 Trial Blinding Schema:  Observer -Blind  
Background and Rationale:  
Dengue fever is caused by [CONTACT_185663] (DENV), a ribonucleic acid virus that occurs as 
4 recognized serotypes, DENV -1, DENV -2, DENV -3, or DENV -4. These dengue viruses are transmitted from human 
to human by [CONTACT_1046] (primarily  Aedes aegypti ). The 4 dengue viruses are endemic in Asia, Central and South 
America, the Caribbean, the Pacific Islands, and parts of Africa. There are an estimated 390 million dengue infections 
per year worldwide, which is more than 3 times the previous World Health Organization (WHO) estimate of 50 to 
100 million cases. Every year, around 500,000 cases of dengue hemorrhagic fever (DHF) require hospi[INVESTIGATOR_185645] 2.5%, primarily in children . It is estimated that 3.9 billion pe ople are at risk of dengue 
infection.  
Dengue fever is clinically defined as an acute febrile illness with 2 or more of the following manifestations: headache, 
retro -orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, or leucopenia, and occ urrence at the same 
location and time as other confirmed cases of dengue fever. The most severe forms of dengue infection â€“ DHF and 
dengue shock syndrome (DSS) â€“ are life threatening. Primary infection with any one of the [ADDRESS_219258] a 
secondary infection by [CONTACT_185664] 3 dengue serotypes and may lead to an increased risk of severe disease 
(DHF/DSS).  
Treatment of dengue fever is base d solely on signs and symptoms, with fluid replacement required for hemorrhagic or 
shock cases. An antiviral therapy for dengue virus infection is not available. Preventive measures that rely on 
mosquito control and individual protection are of limited eff icacy, complex to implement and questionable in terms of 
cost-effectiveness. There is a great unmet global public health need for a safe and effective vaccine to reduce the 
morbidity and mortality associated with dengue disease. Vaccine development has foc used on tetravalent vaccines 
that provide protection against all [ADDRESS_219259] tetravalent dengue vaccine (chimeric yellow fever virus -dengue virus tetravalent  
dengue vaccine [CYD -TDV]) has been recently approved in some countries in Asia and Latin America. Initial 
findings showed that vaccine efficacy was different between serotypes and depended on dengue pre -exposure status. 
Additionally, recent analyses found  that people who had not been infected by [CONTACT_185665] a 
higher risk of getting severe disease when they were infected with dengue virus after vaccination with CYD -TDV. 
Hence, there is a continued unmet public health need for safer a nd more efficacious dengue vaccines.  
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate (TDV) - Background:  
[COMPANY_005]â€™s TDV consists of 1 molecularly characterized, attenuated dengue serotype 2 virus strain and 3 chimeric 
recombinant dengue virus strains expressing surface antigens corresponding to dengue serotypes 1 â€“4. The dengue 
serotype 2 strain (TDV -2) is based upon the attenuated laboratory -derived virus, DENV -2 Primary Dog Kidney 
(PDK) -53, originally isolated at Mahidol University, Bangkok, Thailand.  The chimeric, attenuated vaccine strains for 
dengue serotypes 1, 3 and 4 were engineered by [CONTACT_185666], pre -membrane (prM) and envelope 
(E), of TDV -2 with the prM and E genes of the wild type (DENV) virus strains, DENV -1 [ZIP_CODE], DENV -3 [ZIP_CODE] or 
DENV -4 1036 virus, respectively. Thus, TDV is comprised of 4 dengue virus strains: a molecularly characterized, 
attenuated dengue serotype 2 strain (TDV -2), a dengue serotypes 2/1 chimeric strain (TDV -1), a dengue serotypes 2/3 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 14 of 85 
Protocol Version 4.0  28 November 2018  
 
 chimeric strain (TDV -3), and a dengue serotypes 2/4 chimeric strain (TDV -4). 
Non-clinical studies carried out in mice and non -human primates have demonstrated an acceptable safety, 
immunogenicity, and efficacy profile of TDV. Additionally, data from completed phase [ADDRESS_219260] 
enabled the selection of a final TDV dose (lyophilized formulation) and a 2 -dose vaccination regimen 3  months apart 
by [CONTACT_6567] (SC) injection for use in the pi[INVESTIGATOR_176241].  
The current Investigatorâ€™s Brochure contains additional product information and a mor e detailed review of pre -clinical 
and clinical trials.  
Rationale for the Proposed Trial:  
Dengue and yellow fever (YF) viruses belong to the same family of Flaviviridae  and share antigenic determinants, 
which may result in cross -reacting antibodies. They ar e both transmitted between humans by [CONTACT_1046] (primarily 
Aedes aegypti ), and are endemic in tropi[INVESTIGATOR_185646] a high public health impact. The 
YF-17D vaccine which is based on a live, attenuated viral strain, is the only com mercially available YF vaccine 
administered as a single  SC injection. The YF -17D vaccine is highly effective (approaching 100%) and generally safe 
with the exception of very rare cases of vaccine -associated neurotropic and viscerotropic disease. Vaccinatio n against 
YF is required for travelers to certain countries in accordance with the International Health Regulations, and is also 
recommended by [CONTACT_185667].  
The main purpose of this trial is to assess the immunogenicity and safety of the concomitant administration of YF -17D 
vaccine and TDV in healthy subjects aged 18 to 60 years living in country(ies) non -endemic for both dengue and YF. 
Because broader a nd enhanced immune responses following vaccination with a dengue vaccine have been reported in 
YF-immune subjects compared to YF non -immune subjects, a secondary purpose of this trial is to assess the 
immunogenicity and safety of the sequential administrat ion of YF -17D vaccine and the 2 -dose regimen of TDV. To 
maintain the trial blind, a placebo (0.9% sodium chloride [NaCl] solution) will be used. Approximately 900 subjects 
are planned to be enrolled in this trial.  
This trial will be conducted in accordance  with the protocol, the International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use  and Good Clinical Practice (ICH -GCP) Guidelines and applicable 
regulatory requirements.  
Trial Design : 
This is a phase 3, observer -blind, randomized, multi -center trial in [ADDRESS_219261] s will be randomized equally (1:1:1 ratio) to one of the following 
3 trial groups (300 subjects per trial group):  
â€“ Group 1: YF -17D vaccine +placebo concomitantly administered on Day 1 (Month 0 [M0]), first dose of TDV 
administered on Day 90 (Month 3 [M3]), a nd second dose of TDV administered on Day 180 (Month  6 [M6]).  
â€“ Group 2: first dose of TDV+placebo concomitantly administered on Day 1 (M0), second dose of TDV 
administered on Day 90 (M3), and YF -17D vaccine  administered on Day 180 (M6).  
â€“ Group 3: first dose of TDV+YF -17D vaccine  concomitantly administered on Day 1 (M0), second dose of 
TDV administered on Day 90 (M3), and placebo administered on Day 180 (M6).  
Concomitantly administered vaccines will be injected into opposite arms. All subjects will be followed -up for 
[ADDRESS_219262] vaccination (administered approximately [ADDRESS_219263] vaccination), so the trial 
duration will be approximately 360 days (12 months) for each subject.  
A trial population of 900 subjects (300 subjects per trial gr oup) is considered sufficient for the non -inferiority (NI) 
assessment of the immune response to the YF -17D vaccine when concomitantly administered with TDV compared to 
placebo, and for the NI assessment of the immune response to TDV when TDV is concomitant ly administered with 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 15 of 85 
Protocol Version 4.0  28 November 2018  
 
 YF-17D vaccine  compared to placebo.  
Safety parameters include solicited local (injection site) and solicited systemic adverse events (AE) for 7 days (day of 
vaccination+6 days) and 14 days (day of vaccination+13 days) after each vaccination, respectively, unsolicited AEs 
for 28 days (day of vaccination+27 days) after each vaccination, medically attended AEs (MAAE) and serious adverse 
events (SAE) throughout the trial.  
The schematic of the trial design is included as Figure 2.a. 
Figure 2.a        Schematic of Trial Design  
 
Immunogenicity evaluation:  
Blood samples for the measurement of dengue  neutralizing antibodies (microneutralization test 50% [MNT 50]) will be 
collected at pre -first vaccination (Day 1 [M0]), [ADDRESS_219264] vaccination (Day 30 [Month 1;  M1]), pre -second 
vaccination (Day 90 [M3]), [ADDRESS_219265] second vaccination (Day 120 [ Month 4; M4]), pre -third vaccination 
(Day  180 [M6]), and [ADDRESS_219266] vaccination (Day 210 [Month 7; M7]).  
Blood samples for the measurement of YF neutralizing antibodies (plaque reduction neutralization test [PRNT]) will 
be collected at pre -first va ccination (Day 1 [M0]), [ADDRESS_219267] vaccination (Day 30  [M1]), pre -third vaccination 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 16 of 85 
Protocol Version 4.0  28 November 2018  
 
 (Day 180 [M6]), and [ADDRESS_219268] vaccination (Day 210 [M7]).  
Safety evaluation:  
ï‚· Diary cards (paper or electronic) will be distributed to all subjects for the recording of:  
â€“ Solicited local AEs for 7 days following each vaccination (day of vaccination+6 days). These will include: 
injection site pain, injection site erythema, and injection site swelling, and will be collected at each injection 
site. 
â€“ Solicited syst emic AEs for 14 days following each vaccination (day of vaccination+13 days). These will 
include: fever, headache, asthenia, malaise, and myalgia.  
ï‚· Unsolicited AEs for 28 days following each vaccination (day of vaccination+27 days).  
ï‚· SAEs and MAAEs will be recorded for the trial duration. MAAEs are defined as AEs leading to an unscheduled 
visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness 
criteria.  
Data collection will be by [CONTACT_185668].  
Primary Objective:  
ï‚· To demonstrate NI of the YF seroprotection rate response to 1 dose of YF -17D vaccine,  1 month following 
concomitant administration with 1 dose of TDV compared to placebo.  
Secondary Objectives:  
Immunogenicity  
ï‚· To demonstrate N I of the geometric mean titer (GMT) response to TDV for all [ADDRESS_219269] dose of TDV with YF -17D vaccine  or 
placebo.  
ï‚· To demonstrate NI of the GMT response to 1 dose of  YF-17D vaccine,  1 month following concomitant 
administration with 1 dose of TDV compared to placebo.  
ï‚· To describe the seropositivity rates for all [ADDRESS_219270] dose of  TDV with YF -17D vaccine  or placebo.  
ï‚· To describe the GMTs of neutralizing antibodies and the seropositivity rates for all [ADDRESS_219271] dose of TDV administered concomitantly with YF -17D vaccine  or placebo.  
ï‚· To describe the GMT and seroprotection rate response to YF -17D vaccine,  1 month after sequential administration 
of a 2 -dose regimen of TDV at 0 and 3 months, followed by [CONTACT_185669] -17D vaccine  3 months later.  
ï‚· To describe the GMTs of neutralizing antibodies and the  seropositivity rates for all 4 dengue serotypes, 1  month 
after sequential administration of YF -17D vaccine  at month 0, followed by a 2 -dose regimen of TDV 3 months 
later at 3 and 6 months.  
Safety  
ï‚· To assess the safety profile after each vaccine injection i n Groups 1, [ADDRESS_219272] Population:  
Healthy Subjects : Yes  
Planned Minimum Age: 18 years  
Planned Maximum Age:  60 years  
Planned Number of Subjects: 900 
Planned Number of Groups: Three groups in a 1:1:1 ratio  (300 subjects in each of Groups 1, 2, and 3)  
Criteria for Inclusion:  
1. The subject is aged 18 to 60 years, inclusive.  
2. Individuals who are in good health at the time of entry into the trial as determined by [CONTACT_9870], physical 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 17 of 85 
Protocol Version 4.0  28 November 2018  
 
 examination (including vital signs), and the clinical judgment of the  Investigator.  
3. The subject signs and dates a written informed consent form and any required privacy authorization prior to the 
initiation of any trial procedures, and after the nature of the trial has been explained according to local regulatory 
requiremen ts. 
4. Individuals who can comply with trial procedures and are available for the duration of follow -up. 
Criteria for Exclusion:  
1. Individuals with an elevated oral temperature â‰¥ 38Â°C (100.4Â°F) within 3 days of the intended date of vaccination 
(consider whether applicable as an exclusion criterion or criterion for delay, see below).  
2. Known hypersensitivity or allergy to any of the trial vaccine components (including excipi[INVESTIGATOR_185647]).  
3. Individuals with contraindications , warnings and/or precautions to vaccination with the YF -17D vaccine as 
specified within the product information (especially history of thymus dysfunction).  
4. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opi[INVESTIGATOR_689], 
may interfere with the subjectâ€™s ability to participate in the trial.  
5. Individuals with any history of progressive or severe neurologic disorder, seizure disorder or neuro -inflammatory 
disease (e.g., Guillain -BarrÃ© syndrome).  
6. Individuals w ith a history of or any current illness that, in the opi[INVESTIGATOR_689], might interfere with the 
results of the trial or pose additional risk to the subjects due to participation in the trial.  
7. Known or suspected impairment/alteration of immune fu nction, including:  
a) Chronic use of oral steroids (equivalent to 20 mg/day prednisone â‰¥12 weeks/â‰¥2 mg/kg body weight/day 
prednisone â‰¥2 weeks) within 60 days prior to Day 1 (M0) (use of inhaled, intranasal, or topi[INVESTIGATOR_185648]).  
b) Receipt of p arenteral steroids (equivalent to 20 mg/day prednisone â‰¥12 weeks/â‰¥ 2 mg/kg body weight/day 
prednisone â‰¥2 weeks) within 60 days prior to Day 1 (M0).  
c) Administration of immunoglobulins and/or any blood products within the 3 months prior to Day  1 (M0) or 
plann ed administration during the trial.  
d) Receipt of immunostimulants within 60 days prior to Day 1 (M0).  
e) Immunosuppressive therapy such as anti -cancer chemotherapy or radiation therapy within 6  months prior to 
Day 1 (M0).  
f) Human immunodeficiency virus (HIV) infe ction or HIV -related disease.  
g) Hepatitis C virus infection.  
h) Genetic immunodeficiency.  
8. Abnormalities of splenic or thymic function.  
9. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding 
time.  
10. Individua ls with any serious chronic or progressive disease according to the judgment of the Investigator (e.g., 
neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).  
11. Individuals with body mass index (BMI) greater than or equal to 35 kg/m2 (=wei ght in kg/[height in meters2]). 
12. Individuals or their first degree relatives involved in the trial conduct.  
13. Intent to travel to dengue or YF endemic countries during the trial period.  
14. Individuals with history of substance or alcohol abuse within the past 2 years.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219273] 2 months prior to Day 1 (M0).  
18. Females of childbearing potential who are sexually active and who refuse to use an acceptable contraceptive 
method up to [ADDRESS_219274] vaccination on Day  180 (M6). In addition, they must be advised not to do nate ova 
during this period.  
19. Individuals participating in any clinical trial with another investigational product 30 days prior to Day 1 (M0) or 
intent to participate in another clinical trial at any time during the conduct of this trial.  
20. Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live 
vaccines) prior to enrollment in this trial or who are planning to receive any non -trial vaccine within 28 days of 
trial vaccine administration.  
21. Previous and planned  vaccination (during the trial conduct), against any flavivirus including dengue, YF, 
Japanese encephalitis (JE) or tick -borne encephalitis viruses.  
22. Previous participation in any clinical trial of a dengue or other flavivirus (e.g., West Nile [WN] virus) c andidate 
vaccine, except for subjects who received placebo in those trials.  
23. Subjects with a current or previous infection with a flavivirus such as dengue, Zika, YF, JE, WN fever, or Saint 
Louis encephalitis viruses and subjects with a history of prolonged  (â‰¥1 year) habitation in a dengue endemic area.  
There may be instances when individuals meet all entry criteria except one that relates to transient clinical 
circumstances (e.g., body temperature elevation or recent use of excluded medication or vaccine). Under these 
circumstances, eligibility for trial enrollment may be considered if the appropriate window for delay has passed, 
inclusion/exclusion criteria have been rechecked, and if the subject is confirmed to be eligible.  
Criteria for delay of second or third vaccination  at Day 90 (M3) and Day 180 (M6):  
After enrollment, subjects may encounter clinical circumstances that warrant a delay in the administration of the trial 
vaccination. These situations are listed below. In the event that a subject meets a c riterion for delay of vaccination, the 
subject may receive trial vaccination once the window for delay has passed as long as the subject is otherwise eligible 
for trial participation. The decision to vaccinate in those situations will be made by [CONTACT_24342].  
1. Body temperature â‰¥38.0Â°C (â‰¥100.4Â°F) within 3 days of intended trial vaccination, and/or use of antipyretics 
and/or analgesic medication for either reason within 24 hours prior to vaccine administration.  
2. Receipt of any vaccine other than the trial v accines within 14 days (for inactivated vaccines) or 28 days (for 
live vaccines) of intended trial vaccination.  
3. Known or suspected altered or impaired immune function as specified under the exclusion criteria.  
 
Contraindications to vaccination at Day 90 (M3) and Day 180 (M6):  
                                                 
[ADDRESS_219275] onset of menarche and not meeting any of the following conditions: bilateral tubal ligation (at 
least 1 year previously), bilateral oophorectomy (at least 1 year previously) or hysterectomy.  
2 One or more of the following: hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical 
ring), barrier method (condom with spermicide or diaphragm with spermicide) each and every time during intercourse; 
intrauterine device, monogamous relationship with vasectomized partner (partner must have been vasectomized for at 
least 6 months prior to Day 1 [M0]). Other contraceptive methods may be considered in agreement with the Sponsor 
and will be approved by [CONTACT_57123].  
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
7DNHGDÂ¶V7HWUDYDOHQW'HQJXH9DFFLQH&DQGLGDWH 
7ULDO1R'(1 3DJHRI
3URWRFRO9HUVLRQ 1RYHPEHU

7KHUHDUHDOVRFLUFXPV WDQFHVXQGHUZKLFKUHFHLSWRIWKHYDFFLQD WLRQDW'D\0DQG'D\0LV
FRQWUDLQGLFDWHGLQWKLVWULDO7KHVHFLUFXPVWDQFHVLQFOXGHEXW DUHQRWOLPLWHGWRDQDSK\OD[LVRUVHYHUHK\SHUVHQVLWLYLW\
UHDFWLRQVIROORZLQJWKHDGPLQLVWUDWLRQRIILUVWRUVHFRQGWULDOYDFFLQDW LRQDW'D\0RU'D\ 0UHVSHFWLYHO\
,IWKHVHUHDFWLRQVRFFXUWKHVXEMHFWPXVWQRWUHFHLYHWKHWULD OYDFFLQDWLRQDW'D\ 0RU'D\0
UHVSHFWLYHO\EXWLVHQFRXUDJHGWRF RQWLQXHWULDOSDUWLFLSDWLRQIRUVDIHW\IROORZXS
7ULDO9DFFLQHV 
7'9
7KHLQYHVWLJDWLRQDOYDFFLQH7 '9LVDWHWUDYDOHQWGHQJXHYDFFL QHFDQGLGDWHFRPSULVHGRIPROHFXODUO\
FKDUDFWHUL]HGDWWHQXDWHGGHQJXHYL UXVVWUDLQDQGFKLPHULFG HQJXHYLUXVVWUDLQV ZLWK 
7'97'97'9DQG7'9 UHVSHFWLYHO\7'9LV
DO\RSKLOL]HGYDFFLQHWKDWZLOOEHUHFRQVWLWXWHGLQGLOXHQW P01D&OVROXWLRQSULRUWRDGPLQLVWUDWLRQ 
/LFHQVHG<)'YDFFLQH 
7KHOLFHQVHG<) 'YDFFLQH6DQRIL3DVWHXULVDOLYHDWWHQXDWHG<)YDFFLQHFR QWDLQLQJQRWOHVVWKDQ ORJ
SODTXHIRUPLQJXQLWVRU,8SHUGRVHRIWKH' VWUDLQRIWKH<)YLUXV<) 'YDFFLQHLVO\RSKLOL]HGDQG
ZLOOEHUHFRQVWLWXWHGLQGLOXHQW1D&OIRULQMHFWLRQSULRUWRDGPLQLVW UDWLRQ
3ODFHER
3ODFHERLVDQRUPDOVDOLQHVROXWLRQ1D&OIRULQMHFWLRQ 
5RXWHRIDGPLQLVWUDWLRQ7'9<) 'YDFFLQHDQGSODFHERZLOOEHDG PLQLVWHUHGE\WKH6&URXWH 
'XUDWLRQRIWKH7ULDO
7KHWULDOGXUDWLRQIRUHDFKVXEMHFWZLOOEHDSSUR[LPDWHO\
GD\VPRQWKV 3HULRGRI(YDOXDWLRQ
)RUWKHGXUDWLRQRIDVXEMHFWÂ¶VSDUWLFLSDWLRQ 
0DLQ&ULWHULDIRU(YDOXD WLRQDQG$QDO\VHV
3ULPDU\(QGSRLQW 
x3URSRUWLRQRIVXEMHFWV<)DQG' (19QDLYHDW%DVHOLQHZKRDUHVH URSURWHFWHGDJDLQVW<)RQ'D\ 0DV
PHDVXUHGE\3517<)VHURSUR WHFWLRQUDWH<)VHURSURWHFWLRQLV GHILQHGDVUHFLSURFDODQWL <)QHXWUDOL]LQJ
DQWLERG\WLWHUÂ•,PPXQRORJLFDOQD LYHW\WR<)DQG'(19LVGHI LQHGDV%DVHOLQHUHFLSURFDOQHXWUDOL]LQJ
DQWLERG\WLWHUVIRU<)DQGIRUWKHGHQJXHVHURW\SHV
6HFRQGDU\(QGSRLQWV 
,PPXQRJHQLFLW\ 
x*07RIQHXWUDOL]LQJDQWLERGLHV017 IRUHDFKRIWKHGHQJXHVHURW\SHVDWSUHVHFRQGDQG WKLUGYDFFLQDWLRQV
'D\>0RQWK0 @DQG'D\>0RQWK0@UHVSHFWLYHO\DQGPRQWKSRVWI LUVWVHFRQGDQGWKLUG
YDFFLQDWLRQV'D\>0@'D\>0RQWK0@DQG'D\> 0RQWK0@UHVSHFWLYHO\LQVXEMHFWV<)
DQG'(19QDLYHDW%DVHOLQH
x*07VRIDQWL<)QHXWUDOL]LQJDQ WLERGLHVDWPRQWKSRVWILUVWD QGWKLUGYDFFLQDWLRQV'D\>0@DQG'D\ 
>0@UHVSHFWLYHO\LQVXEMHFWV<)DQG'(19QDLYHDW%DVHOLQH
x6HURSRVLWLYLW\UDWHVRIVXEMHFWVVHURSRVLWLYHIRUHDFKRIW KHGHQJXHVHURW\SHVDWSUHVHFRQGDQGWKLUG
YDFFLQDWLRQV'D\>0@DQG'D\>0@UHVSHFWLYHO\DQG PRQWKSRVWILUVWVHFRQGDQGWKLUG
YDFFLQDWLRQV'D\>0@'D\>0@DQG'D\>0@UHVS HFWLYHO\LQVXEMHFWV<)DQG'(19 QDLYHDW
%DVHOLQHZKHUHVHURSRVLWLYLW\LVGHILQHGDVDUHFLSURFDOQHXWU DOL]LQJDQWLERG\WLWHUÂ•
x6HURSRVLWLYLW\UDWHVRIVXEMHFWVVHURSRVLWLYHIRUPXOWLSOH RUGHQJXHVHURW\SHVDWSUHVHFRQGDQG WKLUG
YDFFLQDWLRQV'D\>0@DQG'D\>0@UHVSHFWLYHO\DQG PRQWKSRVWILUVWVHFRQGDQGWKLUG
YDFFLQDWLRQV'D\>0@'D\>0@DQG'D\>0@UHVS HFWLYHO\LQVXEMHFWV<)DQG'(19 QDLYHDW
%DVHOLQHZKHUHVHURSRVLWLYLW\LVGHILQHGDVDUHFLSURFDOQHXWU DOL]LQJDQWLERG\WLWHUÂ•
x3URSRUWLRQRIVXEMHFWV<)DQG'(19QDLYHDW%DVHOLQHZKRDUHVH URSURWHFWHGDJDLQVW<)DWPRQWKSRVWWKLUGCCI
Property of [COMPANY_005]: For non-commercial us19QDLYHQDLY
RWHFWLRQUDHFWLRQ
RJLFDOQDLYLFDOQ
DQGIRUWKQGIR
OL]LQJDQWL]LQJDQ
RQWK0RQWK
RQV'D\QV'
(19(19se only and subject to the app'9UHVSUHVS
RDGPLQLVDGPLQ
RQWDLQLQJRQWDLQLQ
XV<)<)
ZLOOEHDGOOEHD
HO\3HULRG3HUL
)R)y
on
QDLYQ
07VRIDQ7VRID
>0@UHV>0@UH
6HURS6HUR
YDse
ytyplicable Terms of UseO\
msms
HFXODUO\FXODUO\T
ppl
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 20 of 85 
Protocol Version 4.0  28 November 2018  
 
 vaccination (Day 210 [M7]) as measured by [CONTACT_185670].  
Safety  
ï‚· Frequency and severity of solicited local (injection site[s]) AEs for 7 days (day of vaccination+6 days) and 
solicited systemic AEs for 14 days (day of vacc ination+13 days) after each vaccination.  
ï‚· Percentage of subjects with any unsolicited AEs within 28 days (day of vaccination+27 days) after each 
vaccination.  
ï‚· Percentage of subjects with MAAEs and SAEs throughout the trial.  
Statistical Considerations:  
Analysis sets  
Safety set:  The safety set will consist of all subjects who received at least 1 dose of trial vaccine.  
Full analysis set (FAS): The FAS will include all randomized subjects who received at least [ADDRESS_219276] been received for immunogenicity 
assessments.  
Perâ€“protocol set (PPS): The PPS will exclude all subjects seropositive for dengue virus and seroprotected for YF virus 
at Baseline (seropositivity is define d as a reciprocal neutralizing antibody titer â‰¥10 for the 4 dengue serotypes; YF 
seroprotection is defined as a reciprocal anti -YF neutralizing antibody titer â‰¥10) and will include  all subjects in the 
FAS who have no major protocol violations. The major protocol violation criteria will be defined as part of the blinded 
data review prior to the unblinding of subjectâ€™s trial vaccine assignment. The categories of major protocol violations 
include: (1) not meeting selected entry criteria, (2) not receiving th e planned trial vaccinations or receiving a wrong 
trial vaccine, (3) receiving prohibited therapi[INVESTIGATOR_014], and (4) other major protocol violations that may be identified during 
blinded data reviews.  
All summaries and analyses of safety data will be based on the safety set. The primary immunogenicity analyses will 
be based on the PPS; additional immunogenicity analyses may be provided based on the FAS.  
Analysis of demographics and other Baseline characteristics  
Age, gender, race, and other Baseline characteristics  will be summarized descriptively by [CONTACT_185671]. Unless specified otherwise, number of subjects with non -missing observations, mean, SD, 
median, minimum and maximum will be presented for continuous data; and frequency and perce nt will be presented 
for categorical data.  
Immunogenicity analysis  
Descriptive statistics including 95% CI for the primary and secondary endpoints, including seroprotection rates, 
seropositivity rates and GMTs, will be computed by [CONTACT_185672].  
As a primary analysis, the NI of the immune response to the YF -17D vaccine when concomitantly administered with 
TDV (Group 3) compared to concomitant administration of the YF -17D vaccine with placebo (Group  1) will be 
assessed in terms of YF seroprotection rates on Day 30 (M1). NI will be concluded if the upper bound of the 95% CI 
for the seroprotection rate difference (Group 1 minus Group 3) is less than the NI margin of 5%. The Newcombe score 
method will be used to  compute the 95% CI of the rate difference.  
Secondary analyses will be performed as follows:  
The NI of the immune response to TDV when concomitantly administered with YF -17D vaccine (Group  3) compared 
to concomitant administration of TDV with placebo (Grou p 2) will be assessed in terms of the GMTs of neutralizing 
antibodies for all 4 dengue serotypes on Day 120 (M4). NI will be concluded if the upper bound of the 95% CI for the 
GMT ratio (Group 2/Group 3) is less than the NI margin of 2.0. An analysis of va riance (ANOVA) model will be used 
for this assessment.  
The NI of the immune response to YF -17D vaccine when concomitantly administered with TDV (Group  3) compared 
to concomitant administration of YF -17D vaccine with placebo (Group 1) will be assessed in te rms of the GMTs of 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 21 of 85 
Protocol Version 4.0  28 November 2018  
 
 anti-YF neutralizing antibodies on Day 30 (M1). NI will be concluded if the upper bound of the 95% CI for the GMT 
ratio (Group 1/Group 3) is less than the NI margin of 2.0. An ANOVA model will be used for this assessment.  
Handling of mis sing data and of values below the lower limit of quantification will be described in the statistical 
analysis plan (SAP).  
Safety analysis  
Solicited AEs  
In all subjects the presence and severity (Grade) of solicited local (injection site[s]) AEs (pain, erythema and swelling) 
and solicited systemic AEs (fever, asthenia, malaise, headache and myalgia) will be collected for 7 days and 14 days 
respectively, following each vaccination (including the day of vaccination) via collection of diary cards.  
For each solicited AE, the number and percentage of subjects with local (injection site[s]) and systemic AEs will be 
summarized by [CONTACT_185673] (i.e., Day 1 through Day 7 for local 
[injection site(s)] AEs and Da y 1 through Day 14 for systemic AEs), and overall. Summaries of first onset of each 
event and the number of days subjects reported experiencing each event will also be provided. For subjects with more 
than 1 epi[INVESTIGATOR_177882], the maximum severity will be used for tabulations.  
Persistent/prolonged solicited local or systemic AEs continuing on Day 8 and Day 15, respectively, following each 
trial vaccination will be assessed separately. Unless otherwise specified these AEs will not be included in the 
analyses/tabulations of unsolicited AEs and will have separate listings.  
Unsolicited AEs  
In all subjects, unsolicited AEs will be assessed for 28 days following each vaccination (day of vaccination+27 days).  
Unsolicited AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), and summarized 
by [CONTACT_9560] (PT) and System Organ Class (SOC) for each trial group.  
Unsolicited AEs will be summarized as follows: by [CONTACT_185674] a pre -defined 
frequenc y (the percentage will be specified in the SAP); by [CONTACT_3592]; by [CONTACT_2946], PT, and severity; and by [CONTACT_2946], PT, 
and relationship to the trial vaccine(s). Subjects reporting more than 1 occurrence for the term (level) being 
summarized will be counted only once.  
AEs leading to trial or trial vaccine withdrawal will be collected and summarized for the entire study period.  
MAAEs  
In all subjects, MAAEs will be collected throughout the trial. MAAEs will be coded using MedDRA, and summarized 
by [CONTACT_185675].  
SAEs  
In all subjects, SAEs will be collected throughout the trial. SAEs will be coded using MedDRA, and summarized by 
[CONTACT_185676].  
Sample Size Justification:  
The immunogenicity set sample size calculation assumes a significance  level of 0.025 (one -sided).  
For the primary objective of showing NI in YF seroprotection rates, the calculation assumes a NI margin of 5%, and a 
YF seroprotection rate of 98% at 1 month after YF -17D vaccination in the two trial groups (Group 1 and Group  3). 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 22 of 85 
Protocol Version 4.0  28 November 2018  
 
 For the secondary objective of showing NI in GMTs of neutralizing antibodies for all the 4 dengue serotypes, the 
calculation assumes a NI margin of 2.0, that the true GMT ratio for the two trial groups (Group 2 and Group 3) is 1, 
and that the natural l ogarithm of titers are distributed as normal distributions with SDs of 1.35, 0.86, 1.21, and 1.27.  
For the secondary objective of showing NI in GMTs of anti -YF neutralizing antibodies, the calculation assumes a NI 
margin of 2.0, that the true GMT ratio for  the two trial groups (Group 1 and Group 3) is 1, and that the natural 
logarithm of titers are distributed as normal distributions with a SD of 1.31.  
A sample size of 300 subjects per trial group, with approximately 255 evaluable subjects per trial group ( assuming 
approximately 15% dropouts and non -evaluable subjects), is sufficient to achieve approximately 90% overall power 
for showing NI for the above primary and secondary objectives. A total sample size of 900 subjects also ensures that a 
sufficient numb er of healthy YF/DENV -naive adults will be vaccinated to support the safe use of TDV in travelers.  
The power calculations were based on nQuery AdvisorÂ® 6.01.  
Interim Analysis : 
No interim analyses are planned.  
Data Monitoring Committee:  
A data monitoring committee (DMC) will have oversight of this trial. The DMC functions at a program level and 
further information is available in the DMC Charter . 
DEN -305 Version 4.0 (28 November  2018)  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 23 of 85 
Protocol Version 4.0 28 November 2018  
 
 2.1 Schedule of Trial Procedures  
Visit number  V1 V2 V3 V4 V5 V6 V7 
Day/Month  Day 1  
 
M0 Day 30  
 
M1 Day 90  
 
M3 Day 120  
(V3+30 days)  
M4 Day 180  
(V3+90 days)  
M6 Day 210  
(V5+30 days)  
M7 Day 360  
(V5+180 days)  
M12 (ET) (a) 
Visit window (days)  Â±0 -1/+7 -4/+7 -1/+7 -4/+7 -1/+7 -7/+14  
Signed informed consent (b) X       
Assessment of eligibility criteria (c) X       
Demographics (b) X       
Medical history (b) X       
Concomitant medications/  
vaccinations (d) X X X X X X X 
Check contraindications to vaccination    X  X   
Check criteria for delay of vaccination    X  X   
Complete physical examination (e) X  X  X   
Targeted physical examination (f)  X  X  X X 
Vital signs (g) X X X X X X X 
Pregnancy test (h) X  X  X   
Pregnancy avoidance guidance (i) X X X X X X  
Randomization  X       
Blood Collection  YF neutralizing antibodies 
(10 mL) (j) X X   X X  
Dengue neutralizing 
antibodies (5 mL) (j) X X X X X X  
Vaccine administration  X  X  X   
[ADDRESS_219277] -vaccination in -clinic observation 
including injection site evaluation and body 
temperature measurement (k) X  X  X   
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent D engue Vaccine Candidate   
Trial No. DEN -305 Page 24 of 85 
Protocol Version 4.0  28 November 2018  
 
 Visit number  V1 V2 V3 V4 V5 V6 V7 
Day/Month  Day 1  
 
M0 Day 30  
 
M1 Day 90  
 
M3 Day 120  
(V3+30 days)  
M4 Day 180  
(V3+90 days)  
M6 Day 210  
(V5+30 days)  
M7 Day 360  
(V5+180 days)  
M12 (ET) (a) 
Visit window (days)  Â±0 -1/+7 -4/+7 -1/+7 -4/+7 -1/+7 -7/+[ADDRESS_219278] (l) Distribution  X  X  X   
Review/collection   X  X  X  
Unsolicited AEs (m) X X X X X X  
SAEs (n) X X X X X X X 
MAAEs (n) X X X X X X X 
AEs leading to discontinuation or withdrawal (n) X X X X X X X 
Note: AE=adverse event, ET=early termination, M=Month, MAAE=medically attended adverse event, SAE=serious adverse event, V=vi sit, YF=yellow fever  
Footnotes:  
(a) If the subject terminates early, Day 360 (M12) procedures should be performed.  
(b) Prior to the subject entering into the trial, and before any protocol -directed procedures are performed.  
(c) Review of inclusion/exclusion criteria will be performed prior to the first tri al vaccination at Day 1 (M0).  After written informed consent has been obtained and eligibility is 
assessed, subjects will be randomized to one of the 3 trial groups.  
(d) Any other vaccination against any flavivirus (licensed or investigational, including any o ther dengue vaccine) during the entire trial period, all concomitant medications and 
vaccine history from 1 month (minimum 28 days) prior to administration of each dose of trial vaccine(s) up to 1 month (minimu m 28 days) thereafter, steroids and 
immunostim ulants within 60 days prior to Day  1 (M0), immunoglobulins and blood products within 3 months prior to Day 1 (M0), and immunosuppressive therapy within 6 
months prior to Day 1 (M0).  
(e) Physical examination at Day 1 (M0) including measurement of weight and hei ght; BMI will be calculated automatically. Measurement of height is only required at Day 1  (M0).  
(f) Subjects may undergo a brief symptom -directed physical examination. Clinically significant changes from the Baseline examination should be recorded in the subj ectâ€™s source 
documents and electronic Case Report Form (eCRF).  
(g) Vital signs including (but not limited to) the measurement of systolic blood pressure/diastolic blood pressure, heart rate, a nd body temperature.  
(h) Pregnancy testing (serum or urine) for females of childbearing potential. Results must be confirmed and documented as negative prior to each vaccination. Additional pregnan cy 
tests may be performed during the trial if deemed necessary by [CONTACT_737].  
(i) Females of childbearing potential who are sexua lly active will be provided with information on acceptable methods of contraception and will be asked prior to vaccination on  
Day 1 (M0) to sign the informed consent form stating that they understand the requirements for avoidance of pregnancy and don ation  of ova. Subjects will be reminded during 
trial visits to adhere to acceptable contraceptive methods and not donate ova up to [ADDRESS_219279] trial vaccination at Da y 180 (M6).  
(j) The blood sample on Day  1 (M0), Day 90 (M3) and Day 180 (M6) should be taken prior to trial vaccination. The blood sample on Day  120 (M4) and Day 210 (M7) should be 
taken at least 29 days after the vaccination on Day 90 (M3) and Day  180 (M6), respectively.  
(k) After each trial vaccination, the subject will be observed for at least 30 m inutes including observation for solicited local (injection site) and systemic AEs, unsolicited AEs 
(non-serious and serious), and body temperature measurement.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent D engue Vaccine Candidate   
Trial No. DEN -305 Page 25 of 85 
Protocol Version 4.0  28 November 2018  
 
 (l) Diary (paper or electronic) cards will be used for the collection of:  
1) Solicited local (injec tion site) AEs for 7 days after each vaccination (including the day of vaccination). If solicited local AEs continue on Day [ADDRESS_219280] the extended information on the Adverse Event eCRF.  
      2) Solicited systemic AEs for 1 4 days after each vaccination (including the day of vaccination).  If solicited systemic AEs continue on Day [ADDRESS_219281] the extended information on the Adverse Event eCRF.  
The Investigator will categorize events by [CONTACT_926] (mild, moderate or severe) and will assess causality to vaccine administration for solicited systemic events (related or not 
related).  
(m) Unsolicited AEs for 28 days (including the day of vaccination) after each vaccination will be collected by [CONTACT_185677] 30 (M1), Day 120 (M4) 
and Day 210 (M7). The Investigator will categorize events by [CONTACT_926] (mild, moderate or severe) and will assess causality to  vaccine administration (related or not related).  
(n) AEs leading to discontinua tion or withdrawal, MAAEs and SAEs will be collected for the trial duration. The Investigator will categorize events by [CONTACT_185678] (mild, moderate or 
severe) and will assess causality to vaccine administration (related or not related).  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 26 of 85 
Protocol Version 4.0  28 November 2018  
 
 3.0 TRIAL REFERENCE INFO RMATION  
3.1 Trial -Related Responsibilities  
The Sponsor will perform all trial -related activities with the exception of those identified in the 
â€˜Trial -Related Responsibilitiesâ€™ template. The iden tified vendors in the template for specific 
trial-related activities will perform these activities in full or in partnership with the Sponsor.  
3.2 Principal Investigator/Coordinating Investigator  
[INVESTIGATOR_185649] a  Signatory Principal Investigator/Coordinating Investigator [INVESTIGATOR_185650]. Selection criteria for this Investigator will include 
significant knowledge of the trial protocol, the investigational vaccine, expertise in th e therapeutic 
area and the conduct of clinical research as well as trial participation. The Signatory Principal 
Investigator/Coordinating Investigator [INVESTIGATOR_185651] d escribes the results of the trial.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219282] 50%  
NaCl  Sodium Chloride  
NI Non-inferiority  
PPS Perâ€“Protocol Set  
PRNT  Plaque Reduction Neutralization Test  
PT Preferred Term  
SAE  Serious Adverse Event  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 28 of 85 
Protocol Version 4.0  28 November 2018  
 
 SAP Statistical Analysis Plan  
SC Subcutaneous  
SOC  System Organ Class  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
TDV  Tetravalent Dengue Vaccine Candidate  
TDV -1 Dengue serotypes 2/1 chimeric strain  
TDV -2 Molecularly characterized, attenuated dengue serotype 2 strain  
TDV -3 Dengue serotypes 2/3 chimeric strain  
TDV -4 Dengue serotypes 2/[ADDRESS_219283] Nile  
YF Yellow Fever  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 29 of 85 
Protocol Version 4.0  28 November 2018  
 
 3.4 Corporate Identification  
TV [COMPANY_005] Vaccines, Inc.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 30 of 85 
Protocol Version 4.0  28 November 2018  
 
 4.0 INTRODUCTION  
4.1 Background  
Dengue fever is caused by [CONTACT_185663] (DENV), a ribonucleic acid 
virus that occurs as 4 recognized serotypes, DENV -1, DENV -2, DENV -3, or DENV -4. These 
dengue viruses are transmitted from human to human by [CONTACT_1046] (primarily  Aedes aegypti ). 
The 4 dengue viruses are endemic in Asia, Central and South America, the Caribbean, the Pacific 
Islands, and parts of Africa. There are an estimated 390 million dengue infections per year 
worldwide, which is more than 3 times the previous World Health Organization (WHO) estimate 
of 50 to 100 million cases. Every year, around 500,000 cases of dengue hemorrhagic fever (DHF) 
require hospi[INVESTIGATOR_185652] 2.5%, primarily in children. It is estimated 
that 3.9 billion pe ople are at risk of dengue infection [ 1-4]. 
Dengue fever is clinically defined as an acute febrile illness with 2 or more of the following 
manifestations: headache, retro -orbital pain, myalgia, arthralgia, rash, hemorrhagic 
manifestations, or leucopenia, and occurrence at the same location and time as other confirmed 
cases of dengue fever. The most severe forms of dengue infection â€“ DHF and dengue shock 
syndrome (DSS) â€“ are life threatening. Primary infection with any one of the [ADDRESS_219284] a secondary infection by [CONTACT_185664] 3 dengue serotypes and may lead to an 
increased risk of severe disease (DHF/DSS) [ 3-6]. 
Treatment of dengue fever is based solely on signs and symptoms, with fluid replacement required 
for hemorrhagic or shock cases. An antiviral therapy for dengue virus infection is not available. 
Preventive measures that rely on mosquito control and individual protection are of limited 
efficacy, complex to implement and questionable in terms of cost -effectiveness. There is a great 
unmet global public health need for a safe and effective vaccine to reduce the morbidity and 
mortality associated with dengue disease [ 1-7]. Vaccine development has focused on tetravalent 
vaccines that provide protection against all [ADDRESS_219285] tetravalent dengue vaccine (chimeric 
yellow fever virus -dengue virus tetravalent dengue vaccine [CYD -TDV]) has been recently 
approved in some countries in Asia and Latin America. [ 8]. Initial findings showed that vaccine 
efficacy was different between serotypes and depended on dengue pre -exposure status [ 9]. 
Additionally, recent analyses found that people who had not been infected by [CONTACT_185679] a higher risk of getting sever e disease when they were infected with dengue virus 
after vaccination with CYD -TDV [10]. Hence, there is a continued unmet public health need for 
safer and more efficacious dengue vaccines.  
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate (TDV) - Background:  
[COMPANY_005]â€™s TDV consists of 1 molecularly characterized, attenuated dengue serotype 2 virus strain 
and 3 chimeric  recombinant dengue virus strains expr essing surface antigens corresponding to 
dengue serotypes 1 -4. The dengue serotype 2 strain (TDV -2) is based upon the attenuated 
laboratory -derived virus, DENV -2 Primary Dog Kidney (PDK) -53, originally isolated at Mahidol 
University, Bangkok, Thailand [ 11]. The chimeric, attenuated vaccine strains for dengue serotypes 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 31 of 85 
Protocol Version 4.0  28 November 2018  
 
 1, 3 and 4 were engineered by [CONTACT_185666], pre -membrane (prM)  and envelope 
(E), of TDV -2 with the prM and E genes of the wild type (DENV) virus strains, DENV -1 [ZIP_CODE], 
DENV -3 [ZIP_CODE] or DENV -4 1036 virus, respectively [ 12]. Thus TDV is comprised of 4 dengue 
virus strains: a molecularly characterized, attenuated dengue serotype  2 strain (TDV -2), a dengue 
serotypes 2/1 chimeric strain (TDV -1), a dengue serotypes  2/3 chimeric strain (TDV -3), and a 
dengue serotypes 2 /4 chimeric strain (TDV - 4). 
Non-clinical studies carried out in mice and non -human primates have demonstrated an acceptable 
safety, immunogenicity, and efficacy profile of TDV. Additionally, data from completed phase [ADDRESS_219286] enabled the selection of a final TDV 
dose (lyophilized formulation) and a 2 -dose vaccination regimen 3  months apart by [CONTACT_6567] 
(SC) injection for use in the pi[INVESTIGATOR_176241].  
The current Investigatorâ€™s Brochure for TDV contains additional product information and a more 
detailed review of pre -clinical and clinical trials [ 13]. 
4.2 Rationale for the Proposed Trial  
Dengue and yellow fever (YF) viruses belong to the same family of Flaviviridae  and share 
antigenic determinants, which may result in cross -reacting antibodies [ 14]. They are both 
transmitted between humans by [CONTACT_1046] (primarily Aedes aegypti ), and are endemic in tropi[INVESTIGATOR_185653] a high public health impact. The YF -17D vaccine which is 
based on a live, attenuated viral strain, is th e only commercially available YF vaccine administered 
as a single SC injection. The YF -17D vaccine is highly effective (approaching 100%) and 
generally safe with the exception of very rare cases of vaccine -associated neurotropic and 
viscerotropic disease [ 15]. Vaccination against YF is required for travelers to certain countries in 
accordance with the International Health Regulations [ 16], and is also recommended by [CONTACT_185680] [ 15]. 
The main purpose of this trial is to assess the immunogenicity and safety of the concomitant 
administration of YF -17D vaccine and TDV in healthy subjects age d 18 to 60 years living in 
country(ies) non -endemic for both dengue and YF. Because broader and enhanced immune 
responses following vaccination with a dengue vaccine have been reported in YF -immune subjects 
compared to YF non -immune subjects, a secondary p urpose of this trial is to assess the 
immunogenicity and safety of the sequential administration of YF -17D vaccine and the 2 -dose 
regimen of TDV [ 17, 18]. To maintain the trial blind, a placebo (0.9% sodium chloride [NaCl] 
solution) will be used. Approximately 900 subjects are planned to be enro lled in the trial.  
This trial will be conducted in accordance with the protocol, the International Council for 
Harmonization of Technical Requirements for Pharmaceuticals for Human Use  and Good Clinical 
Practice (ICH -GCP) Guidelines, and applicable regulat ory requirements.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 32 of 85 
Protocol Version 4.0  28 November 2018  
 
 5.0 TRIAL OBJECTIVES AND ENDPOINTS  
5.1 Objectives  
5.1.1 Primary Objective  
ï‚· To demonstrate non -inferiority (NI) of the YF seroprotection rate response to 1 dose of 
YF-17D vaccine,  1 month following concomitant administration with 1 dose of TDV 
compared to placebo.  
5.1.2 Secondary Objectives  
Immunogenicity:  
ï‚· To demonstrate NI of the geometric mean titer (GMT) response to TDV for all [ADDRESS_219287] 
dose of TDV with YF -17D vaccine  or placebo.  
ï‚· To demonstrate NI of the GMT respo nse to 1 dose of YF -17D vaccine,  1 month following 
concomitant administration with 1 dose of TDV compared to placebo.  
ï‚· To describe the seropositivity rates for all [ADDRESS_219288] dose of TDV with YF -17D vaccine  or 
placebo.  
ï‚· To describe the GMTs of neutralizing antibodies and the seropositivity rates for all [ADDRESS_219289] dose of TDV administered concomitantly with YF -17D vaccine  
or placebo.  
ï‚· To descr ibe the GMT and seroprotection rate response to YF -17D vaccine,  1 month after 
sequential administration of a 2 -dose regimen of TDV at 0 and 3 months, followed by [CONTACT_185669] -17D 
vaccine  3 months later.  
ï‚· To describe the GMTs of neutralizing antibodies and the seropos itivity rates for all 4 dengue 
serotypes, 1 month after sequential administration of YF -17D vaccine  at month 0, followed by 
a 2-dose regimen of TDV 3 months later at 3 and 6 months.  
Safety:  
ï‚· To assess the safety profile after each vaccine injection in Group s 1, 2 and 3.  
5.2 Endpoints  
5.2.1 Primary Endpoint  
ï‚· Proportion of subjects YF and DENV -naive at Baseline who are seroprotected against YF on 
Day 30 (Month 1 [M1]) as measured by [CONTACT_185681] (PRNT) (YF 
seroprotection rate). YF seroprotection i s defined as reciprocal anti -YF neutralizing antibody 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 33 of 85 
Protocol Version 4.0  28 November 2018  
 
 titer â‰¥10. Immunological naivety to YF and DENV is defined as Baseline reciprocal 
neutralizing antibody titers <10 for YF and for the 4 dengue serotypes.  
5.2.2 Secondary Endpoints  
Immunogenicity:  
ï‚· GMT of neutr alizing antibodies ( microneutralization test 50% [ MNT 50]) for each of the 
[ADDRESS_219290] vaccinations (Day 90 [Month 3; M3] and Day 180 
[Month  6; M6], respectively); and [ADDRESS_219291] vaccinations (Day 3 0 
[M1], Day  120 [Month 4; M4], and Day 210 [Month 7; M7], respectively) in subjects YF and 
DENV -naive at Baseline.  
ï‚· GMTs of anti -YF neutralizing antibodies at [ADDRESS_219292] vaccinations 
(Day  30 [M1] and Day 210 [M7], respectively) in subjects  YF and DENV -naive at Baseline.  
ï‚· Seropositivity rates (% of subjects seropositive) for each of the [ADDRESS_219293] vaccinations (Day 90 [M3] and Day 180 [M6], respectively); and 
[ADDRESS_219294] vaccinations (Day 30 [M1], Day 120 [M4], and Day 210 
[M7], respectively) in subjects YF and DENV -naive at Baseline, where seropositivity is 
defined as a reciprocal neutralizing antibody titer â‰¥10.  
ï‚· Seropositivity rates (% of subjects seropositive) for multiple (2, 3 or 4) dengue serotypes at 
pre-second and -third vaccinations (Day 90 [M3] and Day 180 [M6], respectively); and 
[ADDRESS_219295] vaccinations (Day 30 [M1], Day 120 [M4], and Day 210 
[M7], respectively) in subjects YF and DENV -naive at Base line, where seropositivity is 
defined as a reciprocal neutralizing antibody titer â‰¥10.  
ï‚· Proportion of subjects YF and DENV -naive at Baseline who are seroprotected against YF at 
[ADDRESS_219296] vaccination (Day 210 [M7]) as measured by [CONTACT_185670].  
Safety:  
ï‚· Frequency and severity of solicited local (injection site[s]) Adverse Events (AE) for 7 days 
(day of vaccination+6 days) and solicited systemic AEs for 14 days (day of vaccination+13 
days) after each vaccination.  
ï‚· Percentage of subjects with any unsolicited  AEs within 28 days (day of vaccination+27  days) 
after each vaccination.  
ï‚· Percentage of subjects with Medically Attended AEs (MAAE ) and Serious AEs (SAE) 
throughout the trial.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 34 of 85 
Protocol Version 4.0  28 November 2018  
 
 6.0 TRIAL DESIGN AND DESCRIPTION  
6.1 Trial Design  
This is a phase 3, observer -blind, rand omized, multi -center trial in 900 healthy adults aged 18 to 
60 years in non -endemic areas for dengue and YF to investigate the immunogenicity and safety of 
the concomitant and sequential administration of TDV and YF -17D vaccine. Subjects will be 
randomized  equally (1:1:1 ratio) to one of the following 3 trial groups (300 subjects per trial 
group):  
ï€­ Group 1: YF -17D vaccine+placebo concomitantly administered on Day 1 (Month [M0]), first 
dose of TDV administered on Day 90 (M3) and second dose of TDV administere d on 
Day 180 (M6).  
ï€­ Group 2: first dose of TDV+placebo concomitantly administered on Day 1 (M0), second dose 
of TDV administered on Day 90 (M3) and YF -17D vaccine administered on Day  180 (M6).  
ï€­ Group 3: first dose of TDV+YF -17D vaccine concomitantly administered on Day 1 (M0), 
second dose of TDV administered  on Day 90 (M3) and placebo administered on 
Day 180 (M6).  
Concomitantly administered vaccines will be injected into opposite arms. All subjects will be 
followed -up for [ADDRESS_219297] vacc ination (administered approximately [ADDRESS_219298] vaccination), so the trial duration will be approximately 360 days (12 months) for each 
subject.  
A trial population of 900 subjects (300 subjects per trial group) is considered sufficient for the  NI 
assessment of the immune response to the YF -17D vaccine when concomitantly administered with 
TDV compared to placebo, and for the NI assessment of the immune response to TDV when TDV 
is concomitantly administered with YF -17D vaccine compared to placebo . 
Safety parameters include solicited local (injection site) and solicited systemic AEs for 7 days (day 
of vaccination+6 days) and 14 days (day of vaccination+13 days) after each vaccination, 
respectively, unsolicited AEs for 28 days (day of vaccination+27  days) after each vaccination, 
MAAEs and SAEs throughout the trial.  
A schematic of the trial design is included as Figure  6.a. A schedule of trial proce dures is provided 
in Section 2.1. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 35 of 85 
Protocol Version 4.0  28 November 2018  
 
 Figure  6.a Schematic of Trial Design  
 
Immunogenicity evaluation:  
Blood samples for the measurement of dengue neutralizing antibodies (MNT 50) will be collected at 
pre-first vaccination (Day 1 [M0]), [ADDRESS_219299] vaccination (Day 30 [M1]), pre -second 
vaccination (Day 90 [M3]), [ADDRESS_219300] second vaccina tion (Day 120 [M4]), pre -third 
vaccination (Day 180 [M6]), and [ADDRESS_219301] vaccination (Day 210 [M7]).  
Blood samples for the measurement of YF neutralizing antibodies (PRNT) will be collected at 
pre-first vaccination (Day 1 [M0]), [ADDRESS_219302]  vaccination (Day 30 [M1]), pre -third 
vaccination (Day 180 [M6]), and [ADDRESS_219303] vaccination (Day 210 [M7]).  
Safety evaluation:  
ï‚· Diary cards (paper or electronic) will be distributed to all subjects for the recording of:  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 36 of 85 
Protocol Version 4.0  28 November 2018  
 
 ï€­ Solicited local AEs for 7 da ys following each vaccination (day of vaccination+6 days). 
These will include: injection site pain, injection site erythema, and injection site swelling, 
and will be collected at each injection site.  
ï€­ Solicited systemic AEs for 14 days following each vaccin ation (day of 
vaccination+13  days). These will include: fever, headache, asthenia, malaise, and myalgia.  
ï‚· Unsolicited AEs for 28 days following each vaccination (day of vaccination+27 days).  
ï‚· SAEs and MAAEs will be recorded for the trial duration. MAAEs are defined as AEs leading 
to an unscheduled visit to or by a healthcare professional including visits to an emergency 
department, but not fulfilling seriousness criteria.  
Data collection will be by [CONTACT_185662] (eCRF).  
6.2 Justification for Trial D esign, Dose, and Endpoints  
The trial design and the collection of solicited AEs, unsolicited AEs (non -serious AEs and SAEs), 
and MAAEs following vaccination are consistent with vaccine evaluation trials.  
Ongoing and completed phase [ADDRESS_219304] enabled th e selection of a final TDV dose (lyophilized 
formulation) and a [ADDRESS_219305] been generally accepted as the immune 
response endpoint for dengue vaccine trials.  
The trial is observer -blind. A placebo ( 0.9% NaCl solution ) will be used at the appropriate time 
point to minimize bias.  
As th e trial will be conducted in non -endemic areas for dengue, a [ADDRESS_219306] trial vaccination is considered adequate.  
A sample size of 300 subjects per trial group (i.e., 900 subjects in total) is considered sufficient for 
the immunogenicity assessments. The  total sample size of 900 subjects is also to ensure that a 
sufficient number of healthy YF/DENV -naive adults will be vaccinated to support the safe use of 
TDV in travelers. Refer to Section 13.2. 
The rationale for the proposed trial is given in Section 4.2. 
6.[ADDRESS_219307]â€™s Expected Participation in the Entire Trial  
The trial duration for each subject will be approximately 360 days (12 months)  including 
vaccination (Day 1 [M0], Day 90 [M3] and Day 180 [M6]) and follow -up through 
Day 360 (Month 12 [M12]).  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 37 of 85 
Protocol Version 4.0  28 November 2018  
 
 6.4 Premature Termination  or Suspension of Trial or Investigational Site  
6.4.1 Criteria for Premature Termination or Suspension of the Trial  
The trial will be completed as planned unless one or more of the following criteria are satisfied that 
require temporary suspension or early termi nation of the trial.  
ï‚· New information or other evaluation regarding the safety or efficacy of the investigational 
vaccine that indicates a change in the known risk/benefit profile, such that the risk/benefit is no 
longer acceptable for subjects participatin g in the trial.  
ï‚· The data monitoring committee (DMC) recommends that the trial should be suspended or 
terminated.  
ï‚· Significant deviation from GCP that compromises the ability to achieve the primary trial 
objectives or compromises subject safety.  
6.4.2 Criteria for  Premature Termination or Suspension of Investigational Sites  
A trial site may be terminated prematurely or suspended if the site (including the Investigator) is 
found in significant deviation from GCP, protocol, or contractual agreement, is unable to ensu re 
adequate performance of the trial, or as otherwise permitted by [CONTACT_82280].  
6.4.3 Procedures for Premature Termination or Suspension of the Trial or the 
Participation of Investigational Site(s)  
In the event that the Sponsor, an institutional re view board (IRB)/independent ethics committee 
(IEC) or regulatory authority elects to terminate or suspend the trial or the participation of an 
investigational site, a trial -specific procedure for early termination or suspension will be provided 
by [CONTACT_37925]; the procedure will be followed by [CONTACT_185682].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 38 of 85 
Protocol Version 4.0  28 November 2018  
 
 7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL  OF SUBJECTS  
All entry criteria, including test results, need to be confirmed prior to ra ndomization . 
7.[ADDRESS_219308] eligibility is determined according to the following criteria:  
1. The subject is aged 18 to 60 years, inclusive.  
2. Individuals who are in good health at the time of entry into the trial as determined by [CONTACT_177964], p hysical examination (including vital signs), and the clinical judgment of the 
Investigator.  
3. The subject signs and dates a written informed consent form and any required privacy 
authorization prior to the initiation of any trial procedures, and after the na ture of the trial has 
been explained according to local regulatory requirements.  
4. Individuals who can comply with trial procedures and are available for the duration of 
follow -up. 
7.[ADDRESS_219309] who meets any of the following criteria will n ot qualify for entry into the trial:  
1. Individuals with an elevated oral temperature â‰¥ 38Â°C (100.4Â°F) within 3 days of the intended 
date of vaccination (consider whether applicable as an exclusion criterion or criterion for 
delay, see below).  
2. Known hypersen sitivity or allergy to any of the trial vaccine components (including excipi[INVESTIGATOR_185654]).  
3. Individuals with contraindications, warnings and/or precautions to vaccination with the 
YF-17D vaccine as specified within the pr oduct information (especially history of thymus 
dysfunction).  
4. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opi[INVESTIGATOR_18959], may interfere with the subjectâ€™s ability to participate in the trial.  
5. Individuals with any history of progressive or severe neurologic disorder, seizure disorder or 
neuro -inflammatory disease (e.g., Guillain -BarrÃ© syndrome).  
6. Individuals with a history of or any current illness that, in the opi[INVESTIGATOR_689], might 
interfere with the results of the trial or pose additional risk to the subjects due to participation 
in the trial.  
7. Known or suspected impairment/alteration of immune function, including:  
a. Chronic use of oral steroids (equivalent to 20 mg/day prednisone â‰¥12 weeks/â‰¥2 mg/kg 
body weight/day prednisone â‰¥2 weeks) within 60 days prior to Day 1 (M0) (use of inhaled, 
intranasal, or topi[INVESTIGATOR_177804]).  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 39 of 85 
Protocol Version 4.0  28 November 2018  
 
 b. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone â‰¥12 weeks/â‰¥2 mg/kg 
body weight/da y prednisone â‰¥2 weeks) within 60 days prior to Day 1 (M0).  
c. Administration of immunoglobulins and/or any blood products within the 3 months prior 
to Day  1 (M0) or planned administration during the trial.  
d. Receipt of immunostimulants within 60 days prior to D ay 1 (M0).  
e. Immunosuppressive therapy such as anti -cancer chemotherapy or radiation therapy within 
6 months prior to Day 1 (M0).  
f. Human immunodeficiency virus (HIV) infection or HIV -related disease.  
g. Hepatitis C virus infection.  
h. Genetic immunodeficiency.  
8. Abno rmalities of splenic or thymic function.  
9. Individuals with a known bleeding diathesis, or any condition that may be associated with a 
prolonged bleeding time.  
10. Individuals with any serious chronic or progressive disease according to the judgment of the 
Inves tigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).  
11. Individuals with body mass index (BMI) greater than or equal to 35 kg/m2 (=weight in 
kg/[height in meters2]). 
12. Individuals or their first degree relatives involved in the trial conduct.  
13. Intent to travel to dengue or YF endemic countries during the trial period.  
14. Individuals with history of substance or alcohol abuse within the past [ADDRESS_219310] 2 months prior to Day 1 (M0).  
18. Females of childbearing potential who are sexually active and who refus e to use an acceptable 
contraceptive method up to [ADDRESS_219311] vaccination on Day  180 (M6). In addition, they 
must be advised not to donate ova during this period.  
                                                 
[ADDRESS_219312] onset o f menarche and not meeting any of the following conditions: bilateral tubal ligation (at 
least 1 year previously), bilateral oophorectomy (at least 1 year previously) or hysterectomy.  
2 One or more of the following: hormonal contraceptive (such as oral, in jection, transdermal patch, implant, cervical 
ring), barrier method (condom with spermicide or diaphragm with spermicide) each and every time during intercourse; 
intrauterine device, monogamous relationship with vasectomized partner (partner must have been  vasectomized for at 
least 6 months prior to Day 1 [M0]). Other contraceptive methods may be considered in agreement with the Sponsor 
and will be approved by [CONTACT_57123].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219313] 3 0 days prior 
to Day 1 (M0) or intent to participate in another clinical trial at any time during the conduct of 
this trial.  
20. Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 
28 days (for live vaccines) prior to enroll ment in this trial or who are planning to receive any 
non-trial vaccine within 28 days of trial vaccine administration.  
21. Previous and planned vaccination (during the trial conduct), against any flavivirus including 
dengue, YF, Japanese encephalitis (JE) or tick-borne encephalitis viruses.  
22. Previous participation in any clinical trial of a dengue or other flavivirus (e.g., West Nile [WN] 
virus) candidate vaccine, except for subjects who received placebo in those trials.  
23. Subjects with a current or previous infe ction with a flavivirus such as dengue, Zika, YF, JE, 
WN fever, or Saint Louis encephalitis viruses and subjects with a history of prolonged 
(â‰¥1 year) habitation in a dengue endemic area.  
There may be instances when individuals meet all entry criteria except one that relates to transient 
clinical circumstances (e.g., body temperature elevation or recent use of excluded medication or 
vaccine). Under these circumstances, eligibility for trial enrollment may be considered if the 
appropriate window for dela y has passed, inclusion/exclusion criteria have been rechecked, and if 
the subject is confirmed to be eligible.  
7.3 Criteria for Delay of Vaccination and/or Blood Sampling  
After enrollment, subjects may encounter clinical circumstances that warrant a delay in the 
administration of trial vaccination. These situations are listed below. In the event that a subject 
meets a criterion for delay of vaccination, the subject may receive trial vaccination once the 
window for delay has passed as long as the subject is oth erwise eligible for trial participation. The 
decision to vaccinate in those situations will be made by [CONTACT_737].  
1. Body temperature â‰¥38.0Â°C (â‰¥100.4Â°F) within 3 days of intended trial vaccination, and/or use 
of antipyretics and/or analgesic medication  for either reason within 24 hours prior to vaccine 
administration.  
2. Receipt of any vaccine other than the trial vaccines within 14 days (for inactivated vaccines) or 
28 days (for live vaccines) of intended trial vaccination.  
3. Known or suspected altered or i mpairment of immune function as specified under the 
exclusion criteria.  
Contraindications to vaccination at Day 90 (M3) and Day 180 (M6):  
There are also circumstances under which receipt of the vaccination at Day 90 (M3) and 
Day 180 (M6) is contraindicated  in this trial. These circumstances include but are not limited to 
anaphylaxis or severe hypersensitivity reactions following the administration of first or second 
trial vaccination at Day 1 (M0) or Day 90 (M3), respectively. If these reactions occur, the subject 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219314] not receive the trial vaccination at Day 90 (M3) or Day 180 (M6), respectively, but is 
encouraged to continue trial participation for safety follow up.  
7.[ADDRESS_219315]â€™s tri al participation may be terminated early. This means that 
no further trial procedures (including data collection) will be performed on that subject beyond the 
specific date of early termination. The primary reason for early termination of the subject from the 
trial should be recorded in the eCRF â€œend of trial visitâ€ page using the following categories. For 
screen failure subjects, refer to Section 9.1.10 . 
1. Adverse Event: The subject has experienced an AE (irrespective of being related/unrelated to 
the trial vaccine or trial -related procedures) that requires early termination because continued 
participation imposes an unacceptable risk to the subjectâ€™s health and/or the subject is 
unwilling to continue participation because of the AE. If the subject is unwilling to continue 
because of the AE the primary reason for early termination in this case will be â€˜withdrawal due 
to AEâ€™ and not â€˜withdrawal of consen tâ€™, see below. Any ongoing AEs leading to early 
termination should be followed by [CONTACT_185683].  
2. Lost to follow -up: The subject did not return to the clinic and at least [ADDRESS_219316] be documented.  
3. Withdrawal of consent: The subject wishes to withdraw from the trial. The primary reason for 
early termination will be â€˜withdrawal of consentâ€ if the subject withdraws from participation 
due to a non -medical reason (i.e., reason other than AE). The reason for withdrawal, if 
provided, should be recorded in the eCRF.  
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded.  
4. Premature trial termination by [CONTACT_2728], a regulatory agency, the IEC/IRB, or any other 
authority.  
If the clinical trial is prematurely terminated by [CONTACT_1034], the Investigator is to promptly 
inform the trial subjects and local EC/IRB  and should ensure appropriate follow up for the 
subjects. The primary reason for early termination in this case will be â€˜trial terminationâ€.  
5. Subjectâ€™s death during trial participation.  
6. Other.  
Note: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219317] will no longer be participating in the trial. In addition to early 
termination criteria (see Section 7.4), other situations may apply in which subjects may continue 
participating in the trial (e.g., contributing safety data according to protocol) but trial vaccine 
administration is discontinued selectively. Regardless of the reasons for discontinuation of trial 
vaccine administration, this must be documented as protocol deviation. Even if the subject is 
deemed ineligible to receive trial vaccine, all efforts should be made to continue the collect ion of 
safety data according to protocol. In addition, the primary  reason for premature discontinuation of 
trial vaccine administration should be recorded in the eCRF â€œend of trial vaccine administrationâ€ 
page using the following categories:  
1. Adverse Event:  The subject has experienced an AE (irrespective of being related/unrelated to 
the trial vaccine or trial -related procedures) for which subsequent trial vaccine administrations 
impose an unacceptable risk to the subjectâ€™s health, but the subject may contin ue trial 
participation for safety, or a subset of other trial procedures.  
2. Lost to follow -up: The subject did not return to the clinic and at least [ADDRESS_219318] be documented.  
3. With drawal of consent: The subject wishes to withdraw from the trial. The primary  reason for 
early termination will be â€œwithdrawal of consentâ€ if the subject withdraws from participation 
due to a non -medical reason (i.e., reason other than AE). The reason for withdrawal, if 
provided, should be recorded in the eCRF.  
4. Premature trial termination by [CONTACT_2728], a regulatory agency, the IEC/IRB, or any other 
authority. If the clinical trial is prematurely terminated by [CONTACT_1034], the Investigator is to 
promptly infor m the trial subjects and local IEC/IRB and should ensure appropriate follow up 
for the subjects. The primary reason for early termination in this case will be â€œtrial 
terminationâ€.  
5. SubjectÂ´s death during trial participation.  
6. Protocol deviation: A protocol deviation is any change, divergence, or departure from the trial 
design or procedures of a trial protocol. The subject may remain in the trial unless continuation 
in the trial jeopardizes the subjectâ€™s health, safety or rights (see Section 7.4). 
7. Pregnancy: Any subject who, despi[INVESTIGATOR_177851], becomes 
pregnant during the trial will not receive further trial vaccine administra tions. Pregnant 
subjects should, however, be asked to continue participating in the trial contributing data to the 
safety follow -up according to protocol (i.e., the pregnant subject will not participate in any 
further trial interventions [e.g., blood colle ction], except for safety follow -up if the subject 
agrees). In addition, the site should maintain contact [CONTACT_185684] a 
â€œPregnancy Formâ€ as soon as possible. The subject should be followed -up until the birth of the 
child, or spon taneous or voluntary termination; when pregnancy outcome information 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 43 of 85 
Protocol Version 4.0  28 November 2018  
 
 becomes available, the information should be captured using the same form. Data obtained 
from the â€œPregnancy Formâ€ will be captured in the safety database.  
8. Receipt of any other dengue vac cines (investigational or licensed) during the trial.  
9. Other  
Note: The specific reasons should be recorded in the â€œspecifyâ€ field of the eCRF.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
7DNHGDÂ¶V7HWUDYDOHQW'HQJXH9DFFLQH&DQGLGDWH 
7ULDO1R'(1 3DJHRI
3URWRFRO9HUVLRQ 1RYHPEHU

&/,1,&$/75,$/0$7(5,$/0$1$*(0(17 
7KLVVHFWLRQFRQWDLQVLQIRUPDWLRQUHJD UGLQJDOOYDFFLQHVDQGPD WHULDOVSURYLGHG GLUHFWO\E\WKH
6SRQVRUDQGRUVRXUFHGE\RWKHUPHDQVWKDWDUHUHTXLUHGE\WK HWULDOSURWRFROLQFOXGLQJLPSRUWDQW
VHFWLRQVGHVFULELQJWKHPDQDJH PHQWRIFOLQLFDOWULDOPDWHULDO 
7ULDO9DFFLQHVDQG0DWHULDOV 
7'9
7KHLQYHVWLJDWLRQDOYDFFLQHLV7'9DWHWU DYDOHQWGHQJXHYDFFLQH FRPSULVHGRIPROHFXODUO\
FKDUDFWHUL]HGDWWHQXDWHGGHQJ XHYLUXVVWUDLQDQGFKLPHULFG HQJXHYLUXVVWUDLQVZLWK 
7'97'97'9
DQG7'9UHVSHFWLYHO\7'9LVDO\RSKLOL]HGYDFFLQHWKDWZLOOEHUHFRQ VWLWXWHGLQGLOXHQW
P01D&OVROXWLRQSULRUWRDGPLQLVWUDWLRQ 
/LFHQVHG<) 'YDFFLQH 
7KHOLFHQVHG<) 'YDFFLQH6DQRIL3D VWHXULVDOLYHDWWH QXDWHG<)YDFFLQHFR QWDLQLQJ 
RIWKH<)YLUXV
<)'YDFFLQHLVO\RSKLOL]HGD QGZLOOEHUHFRQVWLWXWHGLQGLOXHQW 1D&OIRULQMHFWLRQSULRUWR
DGPLQLVWUDWLRQ 
3ODFHER
3ODFHERLVDQRUPDOVDOLQ HVROXWLRQ 1D&OIRULQMHFWLRQ 
'RVDJH)RUP3DFNDJLQJDQG/DEHOLQJ 
7'9NLWV7'9DQG7'9GLOXHQW 
0DQXIDFWXULQJRI PRQRYDOHQWEXONYDFFLQHVXEVWDQFHVRI7'9PL[LQJRIWKH7'9 YDFFLQH
VXEVWDQFHVILOOLQJLQWRYLDOVDQGO\RSKLOL]DWLRQRI7'9LVGR QHDW 

/\RSKLOL]HG7'9LVSUHVHQWHGLQDVLQJOH GRVH 

7'9GLOXHQWP01D&OVROXWLRQLVPDQXIDFWXUHGE\ 



7'9DQG7'9GLOXHQWYLDOVDUHSDFNDJHGWRJH WKHULQWRVLQJOHGRVHGLVSHQVLQJFDUWRQV 7KHYLDOV
ZLOOEHODEHOHGWRFRQWDLQSHUWLQHQWWULDOLQIRUPDWLRQLQORFDO ODQJXDJHV 
/LFHQVHG<) 'YDFFLQHDQGGLOXHQW 
/\RSKLOL]HG<) 'YDFFLQHDQG<) 'YDFFLQHGLOXHQW1D&OIRULQMHFWLRQDUHPDQXIDFWXUHG
E\6DQRIL3DVWHXU 
/\RSKLOL]HG<) 'YDFFLQHLVSUHVHQWHGLQDVLQJOH GRVHYLDOZLWKDVWRSSHUDQGIOLS RIIFDSCCI
CCI
CCICCI
CCI
Property of T7'97'akeda: FoHQWPQWr non-commercial use only andWXWHGLQGXWHGLQ
1D&OI1D&O
DQG/DEQG/
XHQWHQW
HQWEXONQWEXON
LDOVDQGDOVDQ
9LVSUHVHVSUH
ZLOFor 
edaakedTaksubject to the applicable Terms of UseWDQWDQW
RIPROHI PR
WUDLQVZLLQVZ
7'97'9
HFRQVWLWXFRQVW
WHQXDWHGHQXDWHG
nd s
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 45 of 85 
Protocol Version 4.0  28 November 2018  
 
 The diluent (0.5  mL) is provided in a single -use pre -filled syringe.  
Placebo:  
Commercially available normal saline solution for injection (0.9% NaCl) will be used as placebo. 
The placebo is presented in single dose units for 0.5 mL dosing.  
The Sponsor will supply study sites with packaged and labeled TDV, TDV diluent, YF -17D 
vaccine, YF -17D vaccine diluent and placebo. The labels will contai n pertinent trial information in 
local languages. Further details can be found in the Pharmacy Manual.  
8.1.2 Storage  
TDV, YF -17D vaccine, TDV diluent, and YF -17D vaccine diluent will be shipped in refrigerated 
containers at 2Â°C to 8Â°C. From receipt and prior to use, TDV, YF -17D vaccine,TDV diluent, and 
YF-17D vaccine diluent must be stored at 2Â°C to 8Â°C in a refrigerator, do not freeze. TDV and 
YF-17D vaccine  must also be protected from light.  
The placebo will be shipped in ambient conditions and should be stored  per the manufacturerâ€™s 
label.  
All clinical trial material must be kept in an appropriate, limited -access, secure place until it is used 
or returned to the Sponsor or designee for destruction. All Sponsor -supplied vaccines must be 
stored under the conditio ns specified on the label, and remain in the original container until 
dispensed. A daily temperature log of the vaccine storage area must be maintained every working 
day. Temperature excursions must be reported to the Sponsor as soon as possible and use of  these 
trial vaccines and diluents requires Sponsor approval.  
8.1.[ADDRESS_219319] or 
vaccine administrator according to the instructions in the Pharmacy Manual or per Sponsor 
instructions.  
TDV, YF -17D vaccine, and placebo will b e administered by [CONTACT_185685].  
Table  8.a Sponsor -Supplied Vaccines and Placebo  
Trial Group  Number of subjects  Day 1 (M0)  Day 90 (M3)  Day 180 (M6)  
Group 1  300 YF-17D vaccine+placebo  TDV  TDV  
Group 2  300 TDV+placebo  TDV  YF-17D vaccine  
Group 3  300 TDV+YF -17D vaccine  TDV  Placebo  
Note:  Concomitantly administered trial vaccines will be injected in opposite arms.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 46 of 85 
Protocol Version 4.0  28 November 2018  
 
 8.2 Trial Vaccine Assignment and Dispensing Procedures  
The vaccine to be used will be identifiable by  a unique identification number and managed by 
[CONTACT_185686]  (IRT). Refer to Section 8.[ADDRESS_219320] dosing (Day 1 [M0]) to provide the 
necessary subject identifying information.  
The Investigator or designee will use IRT at each dispensing visit to obtain the vaccination 
identification number for the vaccine dose.  
The Investigatorâ€™s designee(s) will be responsible for overseeing the administration of vaccine to 
subjects enrolled in the trial according to the procedures stipulated in this trial protocol. The 
vaccine will be administered only by [CONTACT_185687].  
If Sponsor -supplied vaccine is lost or damaged, the site can request a replacement. Expi[INVESTIGATOR_185655].  
Prior to vaccination, a subject must be determined to be eligible for trial vaccin ation and it must be 
clinically appropriate in the judgment of the Investigator to vaccinate. Eligibility for vaccination 
prior to first trial vaccine administration is determined by [CONTACT_177982] (Section 7.1 and Section 7.2). 
Eligibility for subsequent trial vaccination is determined by [CONTACT_185688]  7.3. 
Trial vaccines should not be administered to individuals with kn own hypersensitivity to any 
component of the vaccines.  
Standard immunization practices are to be observed and care should be taken to administer the 
injection subcutaneously. In addition, the WHO recommendations to reduce anxiety and pain at 
the time of va ccination should be followed [ 19]. Before administering the vaccine, the vaccination 
site is to be disinfected with a skin disinfectant (e.g., 70% alcohol). Allow t he skin to dry. DO NOT 
inject intravascularly.  
As with all injectable vaccines, trained medical personnel and appropriate medical treatment 
should be readily available in case of anaphylactic reactions following vaccination. For example, 
epi[INVESTIGATOR_238] 1:1000 , diphenhydramine, and/or other medications for treating anaphylaxis should 
be available. These rescue medications will not be supplied by [CONTACT_1034].  
8.3 Randomization Code Creation and Storage  
The Sponsor or designeeâ€™s randomization personnel will generate the randomization schedule. 
Randomization information will be stored in a secured area, accessible only by [CONTACT_85983].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 47 of 85 
Protocol Version 4.0  28 November 2018  
 
 8.4 Trial Vaccine Blind Maintenance  
The trial will be conducted in an observer -blind manner; i.e., during the course of the trial, the 
subject and those responsible for the evaluation of any trial endpoint will all be unaware of which 
trial vaccine(s) was administered.  
The Investigator is responsible for the conduct of the trial according to the protocol, however, they 
will be unaware  of which trial vaccine(s) was administered. The unblinded Investigator 
designee(s) will be responsible for preparation, administration, and accountability of trial vaccines 
as specified within the Site Responsibility Delegation Log. The trial vaccines wil l be prepared and 
administered by [CONTACT_185689] (see also Section 8.2). The pharmacist (or 
designated individual) at each site will be responsible for vaccine accountability (see also 
Section  8.6). These unblind ed designees will maintain the trial vaccine blind and will have no role 
in the assessment of subject safety.  
8.5 Unblinding Procedure  
The trial vaccine blind shall not be broken by [CONTACT_185690](s) is necessa ry for the medical treatment of the subject or in case of pregnancy if 
requested by [CONTACT_423]. In the event of a medical emergency or pregnancy, if possible, the 
medical monitor should be contact[CONTACT_185691].  
For unblinding a subject, the trial vaccine blind can be obtained by [CONTACT_737], by [CONTACT_185692]. 
The Sponsorâ€™s Pharmacovigilance Department must be notified as soon as possible if the trial 
vaccine blind is broken by [CONTACT_185693] 24 hours (Section 10.4.4  and Section 9.1.9 , respectively). The date, time, and reason the 
blind is broken must be recorded in the source document and the same information (except the 
time) must be recorded on the eCRF.  
If any subject is unblinded, no further d ose(s) of trial vaccine are to be administered and the subject 
must be withdrawn from the trial.  
8.6 Accountability and Destruction of Sponsor -Supplied Vaccine(s)  
Vaccine supplies will be counted and reconciled at the site before being locally destroyed or 
returned to the Sponsor or designee as noted below. Sites will maintain source documents in 
addition to entering data in IRT.  
The Investigator or designee must ensure that the Sponsor -supplied vaccines (TDV, YF -17D 
vaccine, and placebo) are used in accordance with the approved protocol and are administered only 
to subjects enrolled in the trial. To document appropriate use of Spo nsor-supplied vaccines (TDV, 
YF-17D vaccine, and placebo) , the Investigator or designee must maintain records of all 
Sponsor -supplied vaccine delivery to the site, site inventory, administration and use by [CONTACT_12072], and return to the Sponsor or designe e. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219321], the 
vaccines are received within the labeled storage cond itions (i.e., no cold chain break has occurred 
during transit), and are in good condition. If quantity and conditions are acceptable, the 
Investigator or designees will record receipt of the shipment in the IRT.  
If there are any discrepancies between the p acking list and the actual product received, the Sponsor 
or designee must be contact[CONTACT_45320]. The packing list should be filed in the 
Investigatorâ€™s essential document file by a qualified Investigator designee.  
The pharmacist (or designated individual) at each site must maintain 100% accountability for all 
Sponsor -supplied vaccines received and administered during their entire participation in the trial. 
Proper vaccine accountability includes, but is not limited to:  
ï‚· Verifying that the actual inventory matches the documented inventory.  
ï‚· Verifying that the log is completed for the vaccine lot number used to prepare each dose.  
ï‚· Verifying that all containers used are documented accurately on the log.  
ï‚· Verifying that required fields are completed accu rately and legibly.  
If any dispensing errors or discrepancies are discovered, the Sponsor must be notified 
immediately.  
The pharmacist (or designated individual) at each site must record the current inventory of all 
Sponsor -supplied vaccines (TDV, YF -17D vaccine, and placebo) including TDV diluent and 
YF-17D vaccine diluent on a Sponsor -approved vaccine accountability log. The following 
information will be recorded at a minimum: protocol number and title, name [CONTACT_7919], site 
identifier and number, description of Sponsor -supplied vaccines, expi[INVESTIGATOR_44617]/or retest date, 
and amount. The log (IRT) should include all required information as a separate entry for each 
subject to whom Sponsor -supplied vaccine is administered.  
Prior to site clo sure or at appropriate intervals throughout the trial, before any clinical trial 
materials are destroyed locally or returned to the Sponsor or its designee for destruction, a 
representative from the Sponsor or its designee will perform clinical trial mater ial accountability 
and reconciliation. The Investigator will retain a copy of the documentation regarding clinical trial 
material accountability, return, and/or destruction, and originals will be sent to the Sponsor or 
designee.  
The pharmacist (or designat ed individual) at each site will be responsible for vaccine 
accountability and will document receipt, use, return, or destruction of trial vaccines (TDV, 
YF-17D vaccine, and placebo) including TDV diluent and YF -17D vaccine diluent.  
Vaccine accountability documentation will be reviewed by [CONTACT_185694].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219322] numbers assigned to subjects who fail screening should not be reused (see Section  9.1.10 ). 
9.1.[ADDRESS_219323] eligibility fo r trial participation, such as prior medications/vaccinations, 
concomitant medications/vaccinations, and previous and ongoing illnesses or injuries. Relevant 
medical history can also include any medical history that contributes to the understanding of an A E 
that occurs during trial participation, if it represents an exacerbation of an underlying 
disease/pre -existing problem.  
Any other vaccination against any flavivirus (licensed or investigational, including any other 
dengue vaccine) during the entire trial  period will be recorded in the eCRF irrespective of time of 
administration, and including the vaccine type.  
All concomitant medications and vaccine history from 1 month (minimum 28 days) prior to 
administration of each dose of trial vaccine(s) up to 1 mon th (minimum 28 days) thereafter, 
steroids and immunostimulants within 60 days prior to Day 1 (M0), immunoglobulins and blood 
products within 3 months prior to Day 1 (M0), and immunosuppressive therapy within 6 months 
prior to Day 1 (M0) are to be recorded on the â€œPrior and Concomitant Medicationsâ€ eCRF page 
and in the subjectâ€™s source document. The use of antipyretics and/or analgesic medications within 
[ADDRESS_219324] be identified and the reason for their use (prophylaxis versus 
treatme nt) must be described in the source documents or the eCRF. Trial vaccination should be 
delayed if subjects have used antipyretics and/or analgesic medication for either reason within 
24 hours prior to vaccine administration.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 50 of 85 
Protocol Version 4.0  28 November 2018  
 
 Medications taken for prophylaxis are those intended to prevent the onset of AEs following 
vaccination. Medications taken for treatment are intended to reduce or eliminate the presence of 
symptoms that are present.  
Prohibited Therapi[INVESTIGATOR_014] (see also Section 7.2): 
ï‚· Parenteral immunoglobulin preparation, blood products, and/or blood -derived products within 
the 3 months prior to Day 1 (M0).  
ï‚· Immunosuppressive therapy within 6 mont hs or systemic (e.g., oral or parenteral) 
corticosteroid treatment within 60 days prior to Day 1 (M0) or immunostimulants within 
60 days prior to Day  1 (M0).  
ï‚· Any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) 
prior to Day 1 (M0), Day 90 (M3) and Day 180 (M6), and 28 days after each trial vaccination.  
ï‚· Any other dengue vaccines (investigational or licensed) for the entire trial period.  
ï‚· Receipt of any other clinical trial product for the entire trial period.  
These data must be written in the source documents.  
Medical history (including corresponding medication) to be obtained will include any significant 
conditions or diseases that have disappeared or resolved at or prior to signing of the informed 
consent form.  
9.1.3 Document ation of Trial Entrance/Randomization  
Only subjects who have a signed informed consent form, meet all of the inclusion criteria and none 
of the exclusion criteria are eligible for randomization into the vaccination phase. The 
randomization schedule will be  created and controlled by [CONTACT_178000]. The randomization 
specification will be approved by [CONTACT_1034]â€™s trial statistician or designee.  
If the subject is found to be ineligible for the randomization/vaccination phase, the Investigator 
should record the primary reason for failure on the subject enrollment log.  
9.1.[ADDRESS_219325] be performed by a qualified health professional in accordance with 
local regulations and licensing requirements designated within the Site Respons ibility Delegation 
Log. Complete physical examination will be performed prior to vaccination on Day  1 (M0 ), 
Day 90 (M3), and Day 180 (M6) . A complete physical examination includes but is not limited to: 
auscultation of heart and lungs, palpation of the abd omen, inspection of extremities (including skin 
over intended vaccination site[s]), review of systems, a check of general appearance and the 
measurement of weight and height (measurement of height is only required at Day 1 [M0]) ; BMI 
will be calculated aut omatically. Additional physical examinations may be performed if indicated 
by [CONTACT_98272]â€™s medical  history. The findings should be documented in the subjectâ€™s 
source document.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 51 of 85 
Protocol Version 4.0  28 November 2018  
 
 Targeted physical examination including but not limited to measuremen t of vital signs (see 
Section  9.1.5 ) will be performed at Day 30 (M1), Day 120 (M4), Day 210 (M7 ) and 
Day 360 (M12). Clinical  significant changes f rom the Baseline assessment must be recorded in the 
subjectâ€™s source documents and the eCRF.  
9.1.5 Vital Signs  
These will include (but are not limited to) the measurement of systolic blood pressure, diastolic 
blood pressure, heart rate, and body temperature at all scheduled visits (Day 1 [M0], Day  30[M1], 
Day 90 [M3], Day  120 [M4], Day180 [M6], Day 210 [M7] and Day 360  [M12] ). 
9.1.6 Immunogenicity Assessments  
Blood samples for the measurement of dengue neutralizing antibodies (MNT 50) will be collected at 
pre-first vacc ination (Day 1 [M0]), [ADDRESS_219326] vaccination (Day 30 [M1]), pre -second 
vaccination (Day 90 [M3]), [ADDRESS_219327] second vaccination (Day 120 [M4]), pre -third 
vaccination (Day 180 [M6]), and [ADDRESS_219328] vaccination (Day 210 [M7]). Blood samples  
for the measurement of YF neutralizing antibodies (PRNT) will be collected at pre -first 
vaccination (Day 1 [M0]), [ADDRESS_219329] vaccination (Day 30 [M1]), pre -third vaccination 
(Day 180 [M6]), and [ADDRESS_219330] vaccination (Day 210 [M7]). The ma ximum volume of 
blood taken at any single visit is approximately 15 mL, and the approximate total volume of blood 
for the trial is maximum 70 ml. Refer also to Appendix  D. 
All samples will be collected in accordance with acceptable laboratory procedures. Blood samples 
will be processed and stored at the trial site according to the Laboratory Guidelines as provided in 
the Laboratory Manual.  
9.1.7 Safety Assessments  
Safety assessments will include collection and recording of solicited local (injection site) and 
systemic AEs, unsolicited AEs (non -serious AEs and SAEs), and MAAEs. Refer to Section  10.1 
for safety definitions. Details on collection and reporting of AEs are in Section  10.4 . 
9.1.8 Contraception and Pregnancy Avoidance Proc edure  
For female subjects of childbearing potential, serum or urine pregnancy testing will be performed 
prior to vaccination at Day 1 (M0), Day 90 (M3), and Day 180 (M6). Additional pregnancy tests 
may be performed during the trial if deemed necessary by t he Investigator . Females of 
childbearing potential who are sexually active will be reminded during trial visits to adhere to 
acceptable contraceptive methods up to [ADDRESS_219331] vaccination at Day 180 (M6).  Subjects 
will be provided with information o n acceptable methods of contraception and will be asked prior 
to vaccination on Day 1 (M0) to sign the informed consent form stating that they understand the 
requirements for avoidance of pregnancy and donation of ova . During the course of the trial, 
subje cts of childbearing potential will receive continued guidance with respect to the avoidance of 
pregnancy and donation of ova as part of the trial procedures (Section 2.1); refer also to 
Section  7.2. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219332] be followed to determine outcome, 
including spontaneous or voluntary termination, details of birth, and the presence or absence of 
any birth defects, congenital abnormalities, or maternal and/or newborn complications. This 
follow -up should oc cur even if the intended duration of safety follow -up for the trial has ended. If 
the trial is still ongoing at the time of birth or termination, the women should be further followed 
up for safety until the end of the trial.  
Any pregnancy occurring followi ng trial vaccine administration should be reported immediately, 
using the pregnancy form, to the contact [CONTACT_185695].  
The Investigator must inform the subject of their right to receive trial vaccine information. If the 
subject choo ses to receive unblinded trial vaccine information, the individual blind should be 
broken by [CONTACT_185696]  8.5. 
9.1.[ADDRESS_219333] is 
found to be not eligible at Day 1 (M0), the Investigator should complete the eCRF. The IR T 
supplier should be contact[CONTACT_39804] a notification of non -randomization.  
The primary reason for non -randomization is to be recorded in the eCRF using the following 
categories:  
ï‚· Screen failure (did not meet one or more inclusion criteria or met one or more exc lusion 
criteria).  
ï‚· Withdrawal by [CONTACT_1130].  
ï‚· Trial terminated by [CONTACT_2728].  
Subject numbers assigned to subjects who fail screening should not be reused.  
9.[ADDRESS_219334] in the eCRF.  
9.3 Schedule of Observations and Procedures  
The schedule for all trial -related procedures for all evaluations is shown in Section  2.1. 
Assessments should be completed at the designated visit/time point(s).  
9.3.1 Pre-Vaccination Procedures (Day 1 [M0], Day 90 [M3], and Day 180 [M6])  
1. Before performing any other trial procedure, the  signed informed consent needs to be obtained 
(Day 1 [M0]). Refer to Section 9.1.1. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 53 of 85 
Protocol Version 4.0  28 November 2018  
 
 2. Check inclusion and exclusion criteria (Day 1 [M0]). Refer to Se ction 7.[ADDRESS_219335] demo graphic data (Day 1 [M0]). Refer to Section 9.1.[ADDRESS_219336] medical history (Day 1 [M0]). Refer to Section 9.1.[ADDRESS_219337] concomitant medications/vaccinations. Refer to Section 9.1.2 . 
6. Perform a complete physical examination. Refer to Section 9.1.4 . 
7. Check vital signs. Refer to Section 9.1.5 . 
8. Review of systems: Review of systems is a structured interview that queries the subject as to 
any complaints the subject has experienced across each organ system. Refer to Section  9.1.4 . 
9. Perform pregnancy testing (serum or urine) for female subjects of childbearing potential. Refer 
to Section 9.1.[ADDRESS_219338] (Day 1 [M0]). Refer to Section 9.1.[ADDRESS_219339] pre -vaccination blood sample(s) from all subjects. Refer to Section 9.1.[ADDRESS_219340] using an aseptic venipuncture technique for serological 
immunogenicity testing. Refer to the detailed collection and handling procedures outlined in 
the Laboratory Manual.  
9.3.2 Vaccination Procedures (Day 1 [M0], Day 90 [M3], an d Day 180 [M6])  
1. Check criteria for delay of trial vaccination (Day 90 [M3] and Day 180 [M6]). Refer to 
Section  7.3. 
2. Check contraindications to trial  vaccination (Day 90 [M3] and Day 180 [M6]). Refer to 
Section  7.3. 
3. Vaccinate the subject. Refer to Section 8.1.[ADDRESS_219341]-Vaccination Procedures (Day 1 [M0], Day 90 [M3], and Day 180 [M6])  
1. Careful training of the subject on how to measure solicited local (injection site) AEs and body 
temperature, how to complete the diary card and how often to complete the diary card. 
Training should be directed at the individual(s) who will perform the measurements of local 
AEs and those who will enter the information into the diary card. This individual may or ma y 
not be the subject, but if a person other than the subject enters information into the diary card, 
this personâ€™s identity must be documented in the trial file and this person must receive training 
on the diary card. Training of the subject on how to meas ure an injection site AE should be 
performed while the subject is under [ADDRESS_219342] include the following:  
ï‚· The subject must understand that timely completion of the diary card on a daily basis is a 
critical component of trial participation. In case a paper diary card is used, the subject  
should also be instructed to write clearly and to complete the diary card in pen. Any 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219343] should include a single strikethrough line with a brief explanation for any change and 
be initialed and dated.  
Please note:  
Diary cards will be the only source document allowed for remote collection of solicited local 
(injection site) AEs and systemic AEs (including body temperature measurements). The 
following additional rules apply to the documentation of safety information collected by [CONTACT_185697]:  
ï‚· The diary card should be reviewed with the subject.  
ï‚· No corrections or additions to the diar y card will be allowed after it is reviewed with the 
Investigator/designee.  
ï‚· Any data that are identified as implausible or incorrect, and confirmed by [CONTACT_185698] 
a transcription error should be corrected by [CONTACT_178009] (for paper d iary 
cards, the correction should include a single strikethrough line and should be initialed and 
dated by [CONTACT_423]).  
ï‚· Any blank or illegible fields on the diary card not otherwise corrected as above will be 
missing in the eCRF.  
ï‚· The site must enter all r eadable entries on the paper diary card into the eCRF.  
ï‚· Any newly described solicited safety information should be added to the diary card by [CONTACT_1560] (for paper diary, the new information should be initialed and dated). Any new 
unsolicited safety inform ation would be recorded in the subjectâ€™s source document as a 
verbally reported event and therefore captured as an AE and recorded in the Adverse Event 
eCRF.  
ï‚· Starting on the day of vaccination, the subject will record specific types of events at the 
inject ion site (solicited local AEs), any specific generalized symptoms (solicited systemic 
AEs), daily body temperature (any method), any other symptoms or change in the subjectâ€™s 
health status, and any medications taken (excluding vitamins and minerals). These  
solicited AEs and body temperature will be recorded on the diary card. Assessments should 
preferably take place in the evening at dayâ€™s end.  
ï‚· Body temperature measurement is to be performed using the thermometer provided by [CONTACT_39722]. If the subject feels u nusually hot or cold during the day, the subject should check their 
temperature. The highest body temperature observed that day should be recorded on the 
diary card.  
ï‚· The measurement of solicited local (injection site) AEs (pain, erythema, and swelling) is to 
be performed using the ruler provided by [CONTACT_779].  
2. The collection on the diary card of solicited local (injection site) AEs, and solicited systemic 
AEs (including body temperature) will continue for a total of 7 days and 14 days, respectively, 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 55 of 85 
Protocol Version 4.0  28 November 2018  
 
 following  each trial vaccination. Persistent/prolonged solicited local or systemic AEs 
continuing on Day [ADDRESS_219344] 30  minutes including 
observation for unsolicited AEs (non -serious and serious), solicited local (injection site) and 
systemic AEs, and body temperature measurement. Information should be recorded in the 
electronic data capture system. The Investigator or del egate will take the opportunity to remind the 
subject how to measure solicited AEs and body temperature as part of this observation period. All 
safety data will be collected in the subjectâ€™s source documents.  
The site should schedule the next trial activit y with the subject.  
The subject will receive a written reminder of the next planned trial activity. The subject will be 
reminded to complete the diary card daily and to contact [CONTACT_185699] (or as soon as the subject is medically stable) if the subject becomes 
pregnant or has a medical condition that leads to a hospi[INVESTIGATOR_185656]. All contact [CONTACT_178015].  
9.3.4 Clinic  Visits after Vaccination (Day 30 [M1], Day 120 [M4], Day 210 [M7], and 
Day 360 [M12])  
1. Collect and review the diary card (Day 30 [M1], Day 120 [M4], and Day 210  [M7]).  
2. Collect concomitant medications/vaccinations. Refer to Section 9.1.2 . 
3. Perform a targeted physical examination. Refer to Section 9.1.4 . 
4. Check vital signs. Refer to Section 9.1.5 . 
5. Provide pregnancy avoidance counseling (Day 30 [M1], Day 120 [M4], and Day 210  [M7]). 
Refer to Section 9.1.[ADDRESS_219345] persistent/prolonged solicited AEs  (Day 30 [M1], Day 120 [M4], and Day 210  [M7]) . 
Refer to Sections 9.3.[ADDRESS_219346] unsolicited AEs (Day 30 [M1], Day 120 [M4], and Day 210 [M7]). Refer to 
Section 10.4.1 . 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219347] blood sample(s) from all subjects (Day 30 [M1], Day 120 [M4], and Day 210  [M7]). 
Refer to Section 9.1.[ADDRESS_219348] (Day 30 [M1], Day 120 [M4], and 
Day 210 [M7]).  
The subject will receive a written reminder of the next planned trial activity, as applicable. Th e 
subject will be reminded to complete the diary card daily and to contact [CONTACT_185700] (or as soon as the subject is medically stable) if the 
subject becomes pregnant or has a medical condition th at leads to a hospi[INVESTIGATOR_185657]. All contact [CONTACT_185701].  
9.3.5 Final (End of Trial) Visit  
The Final Visit will be performed at Day 360 (M12). If a subject terminates earli er, end of trial 
visit procedures should be performed if possible. For all subjects receiving trial vaccine or 
placebo, the Investigator must complete the End of Trial eCRF page.  
9.3.[ADDRESS_219349]â€™s 
personal information to ensure optimal confidentiality and defined standard processes for sample 
and data collection, storage, analysis, and destruction.  
Serum samples will be used for the analyses defined in this protocol, but could also, with 
permission from the subject, be used to assess, improve or develop tests related to dengue and 
other disease(s) or the vaccine(s) under trial that will allow more reliable measurement of the 
response to the vaccine(s).  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219350] 
administered a trial vaccine; it does not necessarily have to have a causal relationship with trial 
vaccine administration.  
An AE can therefore be any unfavorable a nd unintended sign (e.g., a clinically significant 
abnormal laboratory finding), symptom, or disease temporally associated with the administration 
of a trial vaccine whether or not it is considered related to the trial vaccine.  
AEs will be graded by [CONTACT_185702]:  
Mild  Grade 1  Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with everyday activities. Relieved with or without symptomatic treatment.  
Moderate  Grade 2  Sufficient discomfort is present to cause interference with normal activity. Only partially 
relieved with symptomatic treatment.  
Severe  Grade 3  Extreme distress, causing significant impairment of functioning or incapacitation. Prevents 
normal everyday activities. No t relieved with symptomatic treatment.  
10.1.2  Solicited Adverse Events  
The occurrence of selected indicators of safety as listed in Table  10.a will be measured/collected 
for 7 days (solicited local [injection site] AEs) and 14 days (solicited systemic AEs) following 
each trial vaccination (including the day of vaccination) and will be recorded on the eCRF, as 
applicable. These will be summarized  in the final report under the category â€œsolicited AEsâ€ to 
differentiate them from other AEs which were not solicited. Any solicited local or systemic AE 
observed as continuing on Day 8 and Day 15, respectively, following each trial vaccination will be 
recorded as an AE on the Adverse Event eCRF for follow -up. For these persistent/prolonged 
solicited AEs the end date will be captured on the Adverse Event eCRF to permit a separate 
analysis from the unsolicited AEs (see Section 10.4.2 ). 
Table  10.a Solicited Local and Systemic AEs  
Solicited local (injection site) AEs:  Pain 
Erythema  
Swelling  
Solicited systemic AEs:  Fever (a) 
Headache  
Asthenia  
Malaise  
Myalgia  
(a) Fever is defined as greater than or equal to 38Â°C (100.4Â°F) regardless of method taken [ 20]. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 58 of 85 
Protocol Version 4.0  28 November 2018  
 
 The severity of solicited safety parameters will be assessed as described in Table  10.b. 
Table  10.b Severity Scales for Solicited Safety Parameters  
Adverse Event  Severity grade  Severity  
Pain at injection site  0 None  
1 Mild: No interference with daily activity  
2 Moderate: Interference with daily activity with or without treatment  
3 Severe: Prevents daily activity with or without treatment  
Erythema at injection 
site (a) 0 <25 mm  
1 Mild: >25 â€“ â‰¤50 mm  
2 Moderate: >50 â€“â‰¤100 mm  
3 Severe: >100 mm  
Swelling at injection 
site (a) 0 <25 mm  
1 Mild: >25 â€“ â‰¤50 mm  
2 Moderate: >50 -â‰¤100 mm  
3 Severe: >100 mm  
Headache  0 None  
1 Mild: No interference with daily activity  
2 Moderate: Interference with daily activity with or without treatment  
3 Severe: Prevents normal activity with or without treatment  
Asthenia  0 None  
1 Mild: No interference with daily activity  
2 Moderate: Interference with daily activity  
3 Severe: Prevents daily activity  
Malaise  0 None  
1 Mild: No interference with daily activity  
2 Moderate: Interference with daily activity  
3 Severe: Prevents daily activity  
Myalgia  0 None  
1 Mild: No interference with daily activity  
2 Moderate: Interference with daily activity  
3 Severe: Prevents daily activity  
Fever (b) Record body temperature in Â°C/Â°F  
(a) Subjects are to record greatest surface diameter in mm on the diary card.  
(b) Fever is defined as greater than or equal to 38Â°C (100.4Â°F) regardless of method taken [ 20]. 
10.1.3  Medically Attended Adverse Events  
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional 
including visits to an emergency department, but not fulfillin g seriousness criteria.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219351] medical occurrence that:  
1. Results in DEATH.  
2. Is LIFE THREATENING.  
ï‚· The term â€œlife threateningâ€ refers to an event in which the subject was at risk of death at the 
time of the ev ent; it does not refer to an event that hypothetically might have caused death 
if it were more severe.  
3. Requires inpatient HOSPI[INVESTIGATOR_117495].  
4. Results in persistent or significant DISABILITY/INCAPACITY.  
5. Leads to a CO NGENITAL ANOMALY/BIRTH DEFECT in the offspring of a subject.  
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:  
ï‚· May require intervention to prevent items 1 through 5 above.  
ï‚· May expose the subject to danger, even though the event is not imme diately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].  
10.2 Causality of Adverse Events  
Relatedness (causality) to vaccine will also be assessed by [CONTACT_737]. The relationship of 
each AE, including solicited systemic AEs (all solicited  local AEs are considered as related) to 
trial vaccine(s) will be assessed using the following categories:  
Related:  There is suspi[INVESTIGATOR_177872] a relationship between the trial vaccine(s) and the 
AE (without determining the extent of probability); there is a reasonable 
possibility that the trial vaccine(s) contributed to the AE.  
Not Related:  There is no suspi[INVESTIGATOR_177872] a relationship between the trial vaccine(s) and 
the AE; there are other more likely causes and administration of the trial 
vaccine(s) is not suspected to have contributed to the AE.  
10.2.1  Relationship to Trial Procedures  
Relationship (causality) to trial procedures should be determined for all AEs.  
The relationship should be assessed as â€œYesâ€ if the Investigator considers that ther e is reasonable 
possibility that an event is due to a trial procedure. Otherwise, the relationship should be assessed 
as â€œNoâ€.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 60 of 85 
Protocol Version 4.0  28 November 2018  
 
 10.2.2  Outcome of Adverse Events  
Resolved:  The subject has fully recovered from the event or the condition has 
returned to the level observed at Baseline.  
Resolving:  The event is improving but the subject is still not fully recovered.  
Not resolved:  The event is ongoing at the time of reporting and the subject has still not 
recovered.  
Resolved with 
sequelae:  As a result of the AE, the  subject suffered persistent and significant 
disability/incapacity (e.g., became blind, deaf or paralysed).  
Fatal:  The subject died due to the event. If the subject died due to other 
circumstances than the event, the outcome of the event per se should be 
stated otherwise (e.g., not resolved or resolving).  
Unknown:  If outcome is not known or not reported.  
10.[ADDRESS_219352] occurrence generally may:  
ï‚· Indicate a new diagnosis or unexpected worsening of a pre-existing condition. Intermittent 
events for pre -existing conditions or underlying disease should not be considered as AEs.  
ï‚· Necessitate therapeutic intervention.  
ï‚· Require an invasive diagnostic procedure.  
ï‚· Require vaccine discontinuation or a change in co ncomitant medication.  
ï‚· Be considered unfavorable by [CONTACT_47392].  
Diagnoses vs. signs and symptoms:  
ï‚· Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values) or symptoms shoul d NOT be recorded as additional AEs. If a 
diagnosis is unknown, signs or symptoms should be recorded appropriately as AEs.  
Worsening of AEs:  
ï‚· If the subject experiences a worsening or complication of an AE after starting administration of 
the trial vaccine( s), the worsening or complication should be recorded as a new AE. 
Investigators should ensure that the AE term recorded captures the change in the condition 
(e.g., â€œworsening ofâ€¦â€).  
ï‚· If the subject experiences a worsening or complication of an AE after any change in trial 
vaccine(s), the worsening or complication should be recorded as a new AE. Investigators 
should ensure that the AE term recorded captures the change in the condition (e.g., â€œworsening 
ofâ€¦â€).  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 61 of 85 
Protocol Version 4.0  28 November 2018  
 
 Changes in severity of AEs:  
ï‚· If the subject experie nces changes in severity of an AE, the event should be captured once with 
the maximum severity recorded.  
Preplanned surgeries or procedures:  
ï‚· Preplanned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of the 
informed consent form ar e not considered AEs. Complications resulting from any planned 
surgery should be reported as AEs.  
Elective surgeries or procedures:  
ï‚· Elective procedures performed where there is no change in the subjectâ€™s medical condition 
should not be recorded as AEs, but  should be documented in the subjectâ€™s source documents. 
Complications resulting from an elective surgery should be reported as AEs.  
10.4 Procedures  
10.4.1  Collection and Reporting of Adverse Events  
All AEs, whether considered related with the use of the trial vaccin e(s) or not, must be monitored 
until symptoms subside and any abnormal laboratory values have returned to Baseline, or until 
there is a satisfactory explanation for the changes observed, or until death, in which case a full 
pathologistâ€™s report should be s upplied, if possible. All findings must be reported on an Adverse 
Event eCRF and on the SAE eCRF form, if necessary (see Section 10.4.2 ). All findings in subjects 
experiencing AEs must also be reported in the subjectâ€™s source documents. Any unsolicited AEs 
for 28 days (day of vaccination+27 days) following each trial vaccination will be collected during 
site visits by [CONTACT_30230]. AEs leading to w ithdrawal from the study or discontinuation of trial 
vaccination have to be reported throughout the trial period.  
The following information will be documented for each event:  
ï‚· Reported term for the AE.  
ï‚· Start and end date.  
ï‚· Serious (Y/N).  
ï‚· Severity.  
ï‚· Investigat orâ€™s opi[INVESTIGATOR_177873] (relationship) between the event and administration of 
trial vaccine(s) (â€œrelatedâ€ or â€œnot relatedâ€).  
ï‚· Investigatorâ€™s opi[INVESTIGATOR_177873] (relationship) to trial procedure(s), including the details 
of the suspected procedu re. 
ï‚· Action taken with the trial vaccine(s).  
ï‚· Outcome of event.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 62 of 85 
Protocol Version 4.0  28 November 2018  
 
 10.4.2  Collection and Reporting of Solicited Adverse Events  
The occurrence of selected indicators of safety will be collected using diary cards completed by [CONTACT_185703] 7 days (solicited local [injection site] AEs) and 14 days (solicited systemic AEs) 
following each trial vaccination (including the day of vacc ination ) and will be recorded on the 
â€œLocal and Systemic AEâ€ eCRF, as applicable. These will be summarized in the final report under 
the category â€œsolicited adverse eventsâ€ to differentiate them from unsolicited AEs. Any solicited 
local (injection site) or  systemic AE observed as continuing on Day 8 and Day 15, respectively, 
following each trial vaccination will be additionally recorded as an AE on the Adverse Event 
eCRF for follow -up. For these persistent/prolonged solicited AEs the end date will be captur ed on 
the Adverse Event eCRF to permit a separate analysis from the unsolicited AEs. Any solicited 
local (injection site) or systemic AE that resolved before 8 days and 15 days, respectively, 
following each trial vaccination, but which recurs at a later ti me (i.e., if discontinued), will be 
recorded as an unsolicited AE on the Adverse Event eCRF.  
Any solicited AE that meets any of the following criteria must be entered as an AE on the Adverse 
Event eCRF:  
ï‚· Solicited local (injection site) or solicited systemi c AEs that lead the subject to withdraw from 
the trial.  
ï‚· Solicited local (injection site) or solicited systemic AEs that lead to the subject being 
withdrawn from the trial by [CONTACT_737].  
ï‚· Solicited local (injection site) or solicited systemic AEs that otherwise meet the definition of 
an SAE (see Section 10.1.2 ). 
10.4.[ADDRESS_219353] trial vaccination (Day 1 [M0]) until the end of the trial 
(Day  360 [M12]) will be collected during site visits by [CONTACT_185704] . 
10.4.[ADDRESS_219354] administered the trial 
vaccines (Day 1 [M0]). Routine collection of SAEs will continue until the end of the trial 
(Day 360 [M12]) . 
SAEs should be reported according to the following procedure:  
A Sponsor SAE form must be completed, in English, and signed by [CONTACT_185705] [ADDRESS_219355] onset or notification of the event. The information should be completed 
as fully as possible but contain, at a minimum:  
ï‚· A short description of th e event and the reason why the event is categorized as serious.  
ï‚· Subject identification number.  
ï‚· Investigatorâ€™s name.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 63 of 85 
Protocol Version 4.0  28 November 2018  
 
 ï‚· Name [CONTACT_178090](s) â€“ if no unblinding is necessary, in a blinded way.  
ï‚· Causality assessment.  
The SAE form should be transmitted wit hin [ADDRESS_219356](s) in the list 
provided to each site.  
Note: For this study, SAE reporting will be performed via eCRF. Only if the electronic data 
capture system is unavailable, a paper Sponsor SAE form should be completed, sign ed by [CONTACT_185706] [ADDRESS_219357] report becomes available at a later date, the 
Investigator should complete a follow -up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copi[INVESTIGATOR_1672] 
(e.g., laboratory tests, discharge summary, post -mortem results) should be sent to the Sponsor.  
All SAEs should be followed up until resolution or permanent outcome of the event or is otherwise 
explained. The timelines and procedure for follow -up reports a re the same as those for the initial 
report.  
10.5.3  Safety Reporting to Investigators, Institutional Review Boards or Independent 
Ethics Committees, and Regulatory Authorities  
The Sponsor or designee will be responsible for the reporting of all suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) and any other applicable SAEs to regulatory authorities, investigators  
and IRBs or IECs, as applicable, in accordance with national regulations in the countries where the 
trial is conducted. Relative to the first awareness of the event by/or further provision to the 
Sponsor or Sponsorâ€™s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_219358] a copy of all expedited reports to 
their IRB or IEC in accordance with national regulations.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219359]-Trial Events  
Any SAE that occurs outside of the protocol -specified observation period or after the end of the 
trial but considered to be caused by [CONTACT_178034](s) must be reported to the Sponsor. These 
SAEs will be processed by [CONTACT_1034]â€™s Pha rmacovigilance Department. Instructions for how to 
submit these SAEs will be provided in a handout in the Investigator Site File.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 65 of 85 
Protocol Version 4.0  28 November 2018  
 
 11.0 TRIAL -SPECIFIC REQUI REMENT(S)  
11.[ADDRESS_219360] oversight of this trial. The DMC functions at a progra m level and further 
information is available in the DMC Charter.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219361] KEEPI[INVESTIGATOR_185658]. 
Adverse events, medical history, and concurrent conditions wi ll be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA, System Organ Class [SOC], High Level Group 
Term, High Level Term, Low Level Term, Preferred Term [PT], and their corresponding 
descriptive terms. Drugs will be coded using the WHO Drug Dictionary.  
12.[ADDRESS_219362] be 
completed in English.  
After completion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable value s. Queries may be issued by [CONTACT_144305] (or designees) and will be answered by [CONTACT_779].  
Corrections to eCRFs are recorded in an audit trail that captures the old information, the new 
information, identification of the person making the correction, t he date the correction was made, 
and the reason for change.  Reasons for significant corrections should additionally be included.  
The Principal Investigator [INVESTIGATOR_185659]. Furthermore, the Investigator must retain 
full responsibility for the accuracy and authenticity of all data entered on the eCRFs . 
Electronic CRFs will be reviewed for completeness and acceptability at the trial site during 
periodic v isits by [CONTACT_55752]. The Sponsor or its designee will be permitted to review the 
subjectâ€™s medical and hospi[INVESTIGATOR_177877]. The 
completed eCRFs are the sole property of the Sponsor and should not be m ade available in any 
form to third parties, except for authorized representatives of appropriate governmental health or 
regulatory authorities, without written permission of the Sponsor.  
12.[ADDRESS_219363] Retention  
The Investigator agrees to keep the records stipulat ed in Section 12.0 and those documents that 
include (but are not limited to) the trial -specific documents, the identification log of all 
participati ng subjects, medical records. Temporary media such as thermal sensitive paper should 
be copi[INVESTIGATOR_57777], source worksheets, all original signed and dated informed consent forms, 
subject authorization forms regarding the use of personal health informat ion (if separate from the 
informed consent form), electronic copy of eCRFs, including the audit trail, and detailed records of 
vaccine disposition to enable evaluations or audits from regulatory authorities, the Sponsor or its 
designees. Furthermore, ICH E 6 Section 4.9.5 requires the Investigator to retain essential 
documents specified in ICH E6 (Section 8) until at least [ADDRESS_219364] 2 years after the investigation is discontinued and regulatory authorities 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 67 of 85 
Protocol Version 4.0  28 November 2018  
 
 are notified. In addition, ICH E6 Section 4.9.5 states that the trial records should be retained until 
an amount of time specified by [CONTACT_185707] a time specified in the 
Clinical Trial Site Agreement between the Investigator and Sponsor.  
Refer to the Clinical Trial Site Agreement for the Sponsorâ€™s requirements on record retention. The 
Investigator should contact [CONTACT_185708].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 68 of 85 
Protocol Version 4.0  28 November 2018  
 
 13.0 STATISTICAL METHODS  
13.1 Statistical and Analytical Plans  
A statistical analysis plan (SAP) will be prepared and finalized prior to unblinding of subjectâ€™s trial 
vaccine assignment. This document will provide further details regarding the definition of analysis 
variables and analysis methodology to address all trial objectives.  
A blinded data review will be conducted prior to unblinding of subjectâ€™s trial vaccine assignment. 
This review wi ll assess the accuracy and completeness of the trial database, subject evaluability, 
and appropriateness of the planned statistical methods.  
13.1.1  Analysis Sets  
Safety set:  The safety set will consist of all subjects who received at least 1 dose of trial vaccine.  
Full analysis set (FAS):  The FAS will include all randomized subjects who received at least 
[ADDRESS_219365] been received for immunogenicity assessments.  
Perâ€“protocol set (PPS):  The PPS will exclude all subjects seropositive for dengue virus and 
seroprotected for YF virus at Baseline (seropositivity is defined as a reciprocal neutral izing 
antibody titer â‰¥10 for the 4 dengue serotypes; seroprotection is defined as a reciprocal anti -YF 
neutralizing antibody titer â‰¥10) and will include all subjects in the FAS who have no major 
protocol violations. The major protocol violation criteria wi ll be defined as part of the blinded data 
review prior to the unblinding of subjectâ€™s trial vaccine assignment. The categories of major 
protocol violations include: (1) not meeting selected entry criteria, (2) not receiving the planned 
trial vaccinations o r receiving a wrong trial vaccine, (3) receiving prohibited therapi[INVESTIGATOR_014], and 
(4) other major protocol violations that may be identified during blinded data reviews.  
All summaries and analyses of safety data will be based on the safety set. The primary 
immuno genicity analyses will be based on the PPS; additional immunogenicity analyses may be 
provided based on the FAS.  
13.1.2  Analysis of Demographics and Other Baseline Characteristics  
Age, gender, race, and other Baseline characteristics will be summarized descriptively by [CONTACT_185709]. Unless specified otherwise, number of subjects with 
non-missing observations, mean, SD, median, minimum and maximum will be presented for 
continuous data; and frequency and percent will be presented  for categorical data.  
13.1.3  Immunogenicity Analysis  
Descriptive statistics including 95% CI for the primary and secondary endpoints, including 
seroprotection rates, seropositivity rates and GMTs, will be computed by [CONTACT_185710] r elevant time points.  
As a primary analysis, the NI of the immune response to the YF -17D vaccine when concomitantly 
administered with TDV (Group 3) compared to concomitant administration of the YF -17D 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 69 of 85 
Protocol Version 4.0  28 November 2018  
 
 vaccine with placebo (Group 1) will be assessed in terms  of YF seroprotection rates on 
Day 30 (M1). NI will be concluded if the upper bound of the 95% CI for the seroprotection rate 
difference (Group 1 minus Group 3) is less than the NI margin of 5%. The Newcombe score 
method [ 21] will be used to compute the 95% CI of the rate difference.  
Secondary analyses will be performed as follows:  
The NI of the immune response to TDV when concomitantly administered with YF -17D vacci ne 
(Group  3) compared to concomitant administration of TDV with placebo (Group 2) will be 
assessed in terms of the GMTs of neutralizing antibodies for all 4 dengue serotypes on 
Day 120 (M4). NI will be concluded if the upper bound of the 95% CI for the GMT  ratio 
(Group  2/Group 3) is less than the NI margin of 2.0. An analysis of variance (ANOVA) model will 
be used for this assessment.  
The NI of the immune response to YF -17D vaccine when concomitantly administered with TDV 
(Group  3) compared to concomitant a dministration of YF -17D vaccine with placebo (Group  1) 
will be assessed in terms of the GMTs of anti -YF neutralizing antibodies on Day 30 (M1). NI will 
be concluded if the upper bound of the 95% CI for the GMT ratio (Group 1/Group 3) is less than 
the NI ma rgin of 2.0. An ANOVA model will be used for this assessment.  
Handling of missing data and of values below the lower limit of quantification will be described in 
the SAP.  
13.1.4  Safety Analysis  
Solicited AEs  
In all subjects, the presence and severity (Grade) of s olicited local (injection site[s]) AEs (pain, 
erythema and swelling) and solicited systemic AEs (fever, asthenia, malaise, headache and 
myalgia) will be collected for 7 days and 14 days respectively, following each vaccination 
(including the day of vaccina tion) via collection of diary cards.  
For each solicited AE, the number and percentage of subjects with local (injection site[s]) and 
systemic AEs will be summarized by [CONTACT_185711] (i.e., Day 1 through Day 7 for local [injection site(s)] AEs and Day 1 through Day  14 
for systemic AEs), and overall. Summaries of first onset of each event and the number of days 
subjects reported experiencing each event will also be provided. For subjects with more than 
1 epi[INVESTIGATOR_177882], the maximum severity will be used for tabulations.  
Persistent/prolonged solicited local or systemic AEs continuing on Day 8 and Day 15, 
respectively, following each trial vaccination will be assessed separately. Unless otherwise 
specified these AEs will not be included in the analyses/tabulations of unsolicited AEs and will 
have separate listings.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 70 of 85 
Protocol Version 4.0  28 November 2018  
 
 Unsolicited AEs  
In all subjects, unsolicited AEs will be assessed for 28 days following each vaccination (day of 
vaccination+27 days).  
Unsolicited AEs will be coded using the MedDRA, and summarized by [CONTACT_185712].  
Unsolicited AEs will be summarized as follows: by [CONTACT_185713] a pre -defined frequency (the percentage will be specified in  the SAP); by [CONTACT_3592]; by 
[CONTACT_2946], PT, and severity; and by [CONTACT_2946], PT, and relationship to the trial vaccine(s). Subjects reporting 
more than 1 occurrence for the term (level) being summarized will be counted only once.  
AEs leading to trial or trial vaccine w ithdrawal will be collected and summarized for the entire 
study period.  
MAAEs  
In all subjects, MAAEs will be collected throughout the trial. MAAEs will be coded using 
MedDRA, and summarized by [CONTACT_185676].  
SAEs  
In all subjects, SAEs wil l be collected throughout the trial. SAEs will be coded using MedDRA, 
and summarized by [CONTACT_185676].  
13.1.5  Interim Analysis and Criteria for Early Termination  
No interim analyses are planned.  
13.2 Determination of Sample Size  
The immunogenicity set sample size calculation assumes a significance level of 0.025 (one -sided).  
For the primary objective of showing NI in YF seroprotection rates, the calculation assumes a NI 
margin of 5%, and a YF seroprotection rate of 98% at 1 month after YF -17D vaccin ation in the two 
trial groups (Group 1 and Group 3).  
For the secondary objective of showing NI in GMTs of neutralizing antibodies for all the 4 dengue 
serotypes, the calculation assumes a NI margin of 2.0, that the true GMT ratio for the two trial 
groups ( Group 2 and Group 3) is 1, and that the natural logarithm of titers are distributed as normal 
distributions with SDs of 1.35, 0.86, 1.21, and 1.27.  
For the secondary objective of showing NI in GMTs of anti -YF neutralizing antibodies, the 
calculation assumes a NI margin of 2.0, that the true GMT ratio for the two trial groups (Group  1 
and Group 3) is 1, and that the natural logarithm of titers are distributed as normal distributions 
with a SD of 1.31 [ 22]. 
A sample size of 300 subjects per trial group, with approximately 255 evaluable subjects per trial 
group (assuming approximately 15% dropouts and non -evaluable subjects), is sufficient to achieve 
approximately  90% overall power for showing NI for the above primary and secondary objectives.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 71 of 85 
Protocol Version 4.0  28 November 2018  
 
 A total sample size of 900 subjects also ensures that a sufficient number of healthy 
YF/DENV -naive adults will be vaccinated to support the safe use of TDV in travelers.  
The power calculations were based on nQuery AdvisorÂ® 6.01.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 72 of 85 
Protocol Version 4.0  28 November 2018  
 
 14.0 QUALITY CONTROL AND QUALITY ASSURANCE  
14.1 Trial -Site Monitoring Visits  
Monitoring visits to the trial site will be made periodically during the trial to ensure that all aspects 
of the protocol are followed . Source documents will be reviewed for verification of data recorded 
on the eCRFs. Source documents are defined as original documents, data, and records. The 
Investigator and institution guarantee access to source documents by [CONTACT_4885] 
(Contract Research Organization) and by [CONTACT_4186].  
All aspects of the trial and its documentation will be subject to review by [CONTACT_16015] 
(as long as blinding is not jeopardized), including but not limited to the Investigatorâ€™s Binder, tr ial 
vaccine, subject medical records, informed consent form documentation, documentation of subject 
authorization to use personal health information (if separate from the informed consent forms), 
and review of eCRFs and associated source documents. It is i mportant that the Investigator and 
other trial personnel are available during the monitoring visits and that sufficient time is devoted to 
the process.  
14.[ADDRESS_219366] to trial subjects. Should other unexpected circumstances arise that will require 
deviation from protocol -specified procedures, the Investigator should consult with the medical 
monitor (and IRB or IEC, as required) to determine th e appropriate course of action. There will be 
no exemptions (a prospective approved deviation) from the inclusion or exclusion criteria.  
14.[ADDRESS_219367] the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the vaccine is sto red and prepared, and any other facility used during the trial. In addition, 
there is the possibility that this trial may be inspected by [CONTACT_17513], including those of 
foreign governments (e.g., the Food and Drug Administration [FDA], the [LOCATION_008] 
Medicines and Healthcare Products Regulatory Agency, the Pharmaceuticals and Medical Devices 
Agency of Japan). If the trial site is contact[CONTACT_63224] a regulatory body, the Sponsor 
should be notified immediately. The Investigator and i nstitution guarantee access for quality 
assurance auditors to all trial documents as described in Section  14.1. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219368] for the individual participants (i.e., subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonized Tripartite Guideline for GCP. Ea ch Investigator will conduct 
the trial according to applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the â€œResponsibilities of the Investigatorâ€ that are listed in Appendix  A. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and Investigator responsibilities.  
15.[ADDRESS_219369] and/or Independent Ethics Committee Approval  
IRBs and IECs must be constituted according to the applicable federal/local requirements of each 
participating region. The Sponsor or designee will require documentation noting all names and 
titles o f members who make up the respective IRB or IEC. If any member of the IRB or IEC has 
direct participation in this trial, written notification regarding his or her abstinence from voting 
must also be obtained. Those [LOCATION_002] (US) sites unwilling to pro vide names and titles of all 
members due to privacy and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by [CONTACT_9930].  
The Sponsor or designee will supply r elevant documents for submission to the respective IRB or 
IEC for the protocolâ€™s review and approval. This protocol, the Investigatorâ€™s Brochure, a copy of 
the informed consent form, and, if applicable, subject recruitment materials and/or advertisements 
and other documents required by [CONTACT_1763], must be submitted to a 
central or local IRB or IEC for approval. The IRBâ€™s or IECâ€™s written approval of the protocol and 
subject informed consent form must be obtained and submitted to the  Sponsor or designee before 
commencement of the trial (i.e., before shipment of the Sponsor -supplied vaccine or trial -specific 
screening activity). The IRB or IEC approval must refer to the trial by [CONTACT_1764], number, 
and version date; identify versions of other documents (e.g.,  informed consent form) reviewed; 
and state the approval date. The Sponsor will notify the site once the Sponsor has confirmed the 
adequacy of site regulatory documentation and, when applicable, the Sponsor has received 
permission from the competent authority to begin the trial. Until the site receives notification no 
protocol activities, including screening may occur.  
Sites must adhere to all requirements stipulated by [CONTACT_1765]. This may include 
notifica tion to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recruitment materials intended for viewing by [CONTACT_1766], local safety reporting requirements, 
reports and updates regarding the ongoing review of the trial at interv als specified by [CONTACT_39820], and submission of the Investigatorâ€™s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
Sponsor or its designee.  
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by [CONTACT_47400].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219370] authorization form (if 
applicable), and subject information sheet (if applica ble) describe the planned and permitted uses, 
transfers, and disclosures of the subjectâ€™s personal and personal health information for purposes of 
conducting the trial. The informed consent form and the subject information sheet (if applicable) 
further exp lain the nature of the trial, its objectives, and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.  
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and if applicable, the subject authorization form. The  informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) must 
be approved by [CONTACT_47401].  
The informed consent form, subject authorization form (if applicable), a nd subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the Investigator to explain the detailed elements of the informed consent 
form, subject authorization fo rm (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by [CONTACT_4186].  
The subject must be given ample opportunit y to: (1) inquire about details of the trial and (2) decide 
whether or not to participate in the trial. If the subject, determines he or she will participate in the 
trial, then the informed consent form and subject authorization form (if applicable) must b e signed 
and dated by [CONTACT_185714]. The 
subject should be instructed to sign using their legal names, not nicknames, using blue or black 
ballpoint ink. The Investigator must also sign a nd date the informed consent form and subject 
authorization (if applicable) at the time of consent and prior to subject entering into the trial; 
however, the Sponsor may allow a designee of the Investigator to sign to the extent permitted by 
[CONTACT_1289] . 
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the Investigatorâ€™s site file. The 
Investigator must document the date the subject signs the infor med consent form in the subjectâ€™s 
medical record and eCRF. Copi[INVESTIGATOR_1681], the signed subject 
authorization form (if applicable), and subject information sheet (if applicable) shall be given to 
the subject.  
All revised informed consent forms must be reviewed and signed by [CONTACT_185715]. The date the revised consent was obtained 
should be recorded in the subjectâ€™s medical record and eCRF, and the subject should receiv e a 
copy of the revised informed consent form.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219371]â€™s right to protection 
against invasion of privacy. Throughout this trial, a subjectâ€™s source data will only be l inked to the 
Sponsorâ€™s clinical trial database or documentation via a unique identification number. As 
permitted by [CONTACT_1763], limited subject attributes, such as sex, age, or date 
of birth, and subject initials may be used to ver ify the subject and accuracy of the subjectâ€™s unique 
identification number.  
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the Sponsor 
requires the Investigator to permit its monitor or designeeâ€™s monitor, representative s from any 
regulatory authority (e.g., FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the Sponsorâ€™s designated auditors, and the 
appropriate IRBs and IECs to review the subjectâ€™s original medical reco rds (source data or 
documents), including, but not limited to, laboratory test result reports, electrocardiogram (ECG) 
reports, admission and discharge summaries for hospi[INVESTIGATOR_1684] a subjectâ€™s 
trial participation, and autopsy reports.  Access to a subjectâ€™s original medical records requires the 
specific authorization of the subject as part of the informed consent form process (see 
Section  15.2). 
Copi[INVESTIGATOR_185660] (i.e., subject name, address, and other identifier fields 
not collected on the subjectâ€™s eCRF).  
15.4 Publication,  Disclosure, and Clinical Trial Registration Policy  
15.4.1  Publication and Disclosure  
The results of this trial are expected to be published in a scientific journal. It is anticipated that 
clinical and laboratory co -investigators will participate in authorship. T he order of authorship and 
choice of journal will be proposed by [CONTACT_185716](s), to be eventually 
agreed upon by [CONTACT_15064]. The data analysis center for this trial will provide the analyses needed 
for publication. Informatio n regarding this trial will be posted on ClinicalTrials.gov.  
15.4.[ADDRESS_219372] information, along 
with Investigatorâ€™s city,  country, and recruiting status will be registered and available for public 
viewing.  
15.4.[ADDRESS_219373] the results of this clinical trial, regardless of outcome, on ClinicalTrials.gov 
or other publicly accessible websi tes, as required by [CONTACT_178066]/or regulations.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219374] is participating. If a lo cal underwriter is required, then the Sponsor or Sponsorâ€™s 
designee will obtain clinical trial insurance against the risk of injury to clinical trial subjects. Refer 
to the Clinical Trial Site Agreement regarding the Sponsorâ€™s policy on subject compensatio n and 
treatment for injury. If the Investigator has questions regarding this policy, he or she should 
contact [CONTACT_13679]â€™s designee.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 77 of 85 
Protocol Version 4.0  28 November 2018  
 
 16.0 REFERENCES  
1. Simmons CP, Farrar JJ, Nguyen VVC, Wills B. Dengue. N Engl J Med 2012;366(15):1423 -32. 
2. Gubler DJ. Ep idemic dengue/dengue hemorrhagic fever as a public health, social and 
economic problem for the 21st century. Trends Microbiol 2002;10(2):100 -3. 
3. Guzman GM, Kouri G. Dengue: an update. Lancet Infect Dis 2002;2(1):[ADDRESS_219375] Sheet. Available at: 
http://www.who.int/mediacentre/factsheets/fs117/en/  [Accessed 28 November  2018] . 
5. World Health Organization, 1997. Dengue hemorrhagic fever: diagnosis, treatment, 
prevention and control, 2nd Edition. Geneva . Available at: 
http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/ [Accessed 
28 November  2018].  
6. World Health Organization, 2009. Dengue guidelines for diagnosis, treatment, prevention and 
control. Available at: http://www.who.int/tdr/ publications/documents/dengue -diagnosis.pdf 
[Accessed 28 November  2018] . 
7. Halstead S, Deen J. The future of dengue vaccines. Lancet 2002;360(9341):1243 -5. 
8. [COMPANY_011] Pasteur, 2018. An informational website about dengue and dengue vaccination for 
media. Availabl e from http://www.dengue.info [Accessed 28 November  2018].  
9. Hadinegoro SR, Arredondo -GarcÃ­a JL, Capeding MR, Deseda C, Chotpi[INVESTIGATOR_185661] T, 
Dietze R, et al . Efficacy and long -term safety of a dengue vaccine in regions of endemic 
disease. N Engl J Med 2015; 373(13):1195 -206. 
10. Simmons CP. A candidate dengue vaccine walks a tightrope. N Engl J Med. 2015. 
373(13):1263 -4. 
11. Yoksan S, Bhamarapravati N, Halstead SB. Dengue virus vaccine development: study on 
biological markers of uncloned dengue 1 -4 viruses serially p assaged in primary kidney cells. 
In: TD St. George, BH Kay and J Blok (ed.), Arbovirus research in Australia. Proceedings of 
the 4th Symposium. CSIRO/QIMR, Brisbane, Australia, 1986: 35 -8. 
12. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kin ney RM. Dengue 2 
PDK -53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol 
2003;77(21):[ZIP_CODE] -47. 
13. Tetravalent Dengue Vaccine Candidate (TDV) Investigatorâ€™s Brochure (IND [ZIP_CODE]), 
Edition  9, [ADDRESS_219376] EG, et al. 
Antigenic relationships between flaviviruses as determined by [CONTACT_12783] -neutralization tests with 
polyclonal antisera. J Gen Virol 1989;70 (Pt 1):37 -43. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219377] yellow fever: WHO Position 
Paper, June 2013 -recommendations. Vaccine 2015;33(1):[ADDRESS_219378], Freedman DO. The revised international health regulations (2005): 
impact on yellow fever vaccination in clinical practice. Am J T rop Med Hyg 
2008;78(3):359 -60. 
17. Dorrance WR, Frankel JW, Gordon I, Patterson PR, Schlesinger RW, Winter JW. Clinical and 
serologic response of man to immunization with attenuated dengue and yellow fever viruses. J 
Immunol 1956;77(5): 352 â€“64. 
18. Scott RM, Eckel s KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, et al. Dengue 
2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis 
1983;148 (6):1055 â€“60. 
19. World Health Organization. Reducing pain at the time of vaccination: W HO position paper â€“
September 2015. Wkly Epi[INVESTIGATOR_75313]. 2015;90(39):505 â€“10. 
20. Kohl KS, Marcy M, Blum M, Jones MC, Dagan R, Hansen J, et al. Fever after immunization: 
current concepts and improved scientific understanding. Clin Infect Dis 2004;39:389 -94. 
21. Newcom be RG. Improved confidence intervals for the difference between binomial 
proportions based on paired data. Stat Med 1998;17(22):2635 -50.  
22. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, et al. Concomitant or 
sequential administration of  live attenuated Japanese encephalitis chimeric virus vaccine and 
yellow fever 17D vaccine: randomized double -blind phase II evaluation of safety and 
immunogenicity. Hum Vaccin 2010;6(11):906 -14. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219379] to ICH GCP and all the applicable 
local laws and regulations.  
The Investigator agrees to assume the following responsibilities:  
1. Conduct the trial in accordance with the proto col. 
2. Personally conduct or supervise the staff who will assist in the protocol.  
3. Ensure that trial -related procedures, including trial -specific (non -routine/non -standard panel) 
screening assessments are NOT performed on potential subjects, prior to the rece ipt of written 
approval from relevant governing bodies/authorities.  
4. Ensure that all colleagues and employees assisting in the conduct of the trial are informed of 
these obligations.  
5. Secure prior approval of the trial and any changes by [CONTACT_4215]/I EC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory requirements.  
6. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all cha nges in research activity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the trial to the 
IRB/IEC, and issue a final report within [ADDRESS_219380]â€™s medical chart. Valid informed consent form is the most 
current versi on approved by [CONTACT_1201]/IEC. Each informed consent form should contain a 
subject authorization Section that describes the uses and disclosures of a subjectâ€™s personal 
information (including personal health information) that will take place in connection wit h the 
trial. If an informed consent form does not include such a subject authorization, then the 
Investigator must obtain a separate subject authorization form from each subject.  
9. Prepare and maintain adequate case histories of all persons entered into the trial, including 
eCRFs, hospi[INVESTIGATOR_1097], laboratory results, etc, and maintain these data for a minimum of 
[ADDRESS_219381] and receive written approval from the Sponsor before disposing of any such 
documents.  
10. Allow possible inspection and copying by [CONTACT_174394] -specified essential 
documents.  
11. Maintain current  records of the receipt, administration, and disposition of Sponsor -supplied 
vaccines, and return all unused Sponsor -supplied vaccines to the Sponsor.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 80 of 85 
Protocol Version 4.0  28 November 2018  
 
 12. Report AEs to the Sponsor promptly. In the event of an SAE, notify the Sponsor within 
24 hours.  
13. Review an d provide a signature [CONTACT_178091].  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219382] and retain personal information of Investigator, including his or her name, 
address, and other personally identifiable information. In addition, Investigatorâ€™s personal 
information may be transferred to other parties located in countries throughout the world (e.g., the 
[LOCATION_008], US, and Japan), including the fol lowing:  
ï‚· [COMPANY_005], its affiliates, and licensing partners.  
ï‚· Business partners assisting [COMPANY_005], its affiliates, and licensing partners.  
ï‚· Regulatory agencies and other health authorities.  
ï‚· IRBs and IECs.  
Investigatorâ€™s personal information may be retained, proces sed, and transferred by [CONTACT_117578]:  
ï‚· Assessment of the suitability of Investigator for the trial and/or other clinical trials.  
ï‚· Management, monitoring, inspection, and audit of the trial.  
ï‚· Anal ysis, review, and verification of the trial results.  
ï‚· Safety reporting and pharmacovigilance relating to the trial.  
ï‚· Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the trial.  
ï‚· Preparatio n and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other vaccines used in other clinical trials that may contain the 
same chemical compound present in the investigational vaccine.  
ï‚· Inspections and i nvestigations by [CONTACT_178082].  
ï‚· Self-inspection and internal audit within [COMPANY_005], its affiliates, and licensing partners.  
ï‚· Archiving and audit of trial records.  
ï‚· Posting Investigator site contact [CONTACT_3031], trial details and results on publicly accessible 
clinical trial registries, databases, and websites.  
Investigatorâ€™s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection la ws in Investigatorâ€™s own 
country. Investigator acknowledges and consents to the use of his or her personal information by 
[CONTACT_4219].  
Please note that this consent will not cover Investigator personnel.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219383]:  
1. A statement that the trial involves research.  
2. An explanation of the purposes of the research.  
3. The expected duration of the subjectâ€™s participation.  
4. A description of the procedures to be followed, including invasive procedures.  
5. The identification of any procedures that are experimental.  
6. The estimated number of subjects involved in the tria l. 
7. A description of the subjectâ€™s responsibilities.  
8. A description of the conduct of the trial.  
9. A statement describing the vaccination(s) and the probability for random assignment to each 
trial group.  
10. A description of the possible side effects following vaccine administration that the subject may 
receive.  
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.  
12. A statement that the vaccinations may involve risks to the su bject (or to the embryo or fetus, if 
the subject is or may become pregnant) which are currently unforeseeable.  
13. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical b enefit to the subject, the subject should be 
made aware of this.  
14. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential risks and benefits.  
15. A statement desc ribing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By [CONTACT_2960] a written informed consent fo rm, the 
subject is authorizing such access.  
16. For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of  or where further information may be obtained.  
17. The anticipated prorated payment(s), if any, to the subject for participating in the trial.  
18. The anticipated expenses, if any, to the subject for participating in the trial.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -[ADDRESS_219384] fo r answers to pertinent questions about the research 
(Investigator), subjectâ€™s rights, and IRB/IEC and whom to contact [CONTACT_44751] a 
research -related injury to the subject.  
20. A statement that participation is voluntary, that refusal to participate will in volve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.  
21. The consequences of a subjectâ€™s decision to withdraw from the research and procedures for 
orderly termination of participation by [CONTACT_423].  
22. A statement that the subject will be informed in a timely manner if information becomes 
available that may be relevant to the subjectâ€™s willingne ss to continue participation in the trial.  
23. A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws require the Sponsor to do so.  
24. The foreseeable circumstances or reasons under which the subjectâ€™s participation in the trial 
may be terminated.  
25. A written subject authorization (either contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subj ectâ€™s personal information (including personal health information) for 
purposes of conducting the trial. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subjectâ€™s personal information:  
a) that personal  information (including personal health information) may be processed by [CONTACT_87859], including, without limitation, to the following: (1) [COMPANY_005], its affiliates, an d 
licensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;  
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, [COMPANY_005] will make every effort to keep your personal information c onfidential, 
and your name [CONTACT_87873] [CONTACT_2371];  
c) that personal information (including personal health information) may be added to 
[COMPANY_005]â€™s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of t he 
safety and effectiveness of the investigational vaccine(s), studying other therapi[INVESTIGATOR_82256], developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of 
future clinical trials;  
d) that subjects agree not to restrict the use and disc losure of their personal information 
(including personal health information) upon withdrawal from the trial to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 84 of 85 
Protocol Version 4.0  28 November 2018  
 
 e) that the subjectâ€™s identity will remain confidential in the event that trial results are 
published.  
26. Female subjects of childbearing potential (e.g., non -sterilized, premenopausal female subjects) 
who are sexually active must use adequate contraception (as defined in the info rmed consent 
form) from at least 2 months prior to Day 1 (M0) up to [ADDRESS_219385] vaccination on 
Day 180 (M6). Pregnancy tests will be performed prior to vaccination at Day  1 (M0), Day  90 
(M3), and Day 180 (M6). Additional pregnancy tests may be perfo rmed during the trial if 
deemed necessary by [CONTACT_737]. Females of childbearing potential who are sexually 
active will be reminded during trial visits to adhere to acceptable contraceptive methods up to 
[ADDRESS_219386] vaccination on Day 180 (M6) . In addition, they must be advised not to 
donate ova during this period. If a subject is found to be pregnant during the trial, no further 
vaccine doses will be administered.  
27. A statement that clinical trial information from this trial will be publicly dis closed in a publicly 
accessible website, such as ClinicalTrials.gov.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
[COMPANY_005]â€™s Tetravalent Dengue Vaccine Candidate   
Trial No. DEN -305 Page 85 of 85 
Protocol Version 4.0  28 November 2018  
 
 APPENDIX  D SEROLOGY PLAN  
Table  16.a Serology Plan  
Timing  Blood volume  Assessments  
Day 1 (M0), Day 30 (M1), Day180 (M6), 
Day 210 days (M7)  10 mL  YF neutralizing antibodies (PRNT)  
Day 1 (M0), Day 30 (M1), Day 90 (M3), 
Day 120 (M4), Day180 (M6) and Day 210 (M7)  5 mL  Dengue neutralizing antibodies (MNT 50) 
M=month, MNT 50=microneutralization test 50%, PRNT=plaque reduction neutralization test.  
Note: Blood sampling at Day 1 (M0), Day 90 (M3) and Day 180 (M6) should be performed prior to vaccination.  
Note: The blood sample on Day 120 (M4) and Day 210 (M7) should be taken at least 29 days after the vaccina tion on 
Day 90 (M3) and Day 180 (M6), respectively.  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
6LJQDWXUH3DJHIRU'(13URWRFRO$PHQGPHQW9HUVLRQ 1RYHPEHU
7LWOH$5DQGRPL]HG2EVHUYHU%OLQG3ODFHER&RQWUROOHG3KDVH 7ULDOWR,QYHVW
'RFXPHQW1XPEHU7$.Y$SSURYDO
$SSURYDO
$SSURYDO
$SSURYDO[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Property of [COMPANY_005]: For non-commercial use only a1XPEHUXPEnlnlysubject to the thplicable Terms of Useble Termscab
he applica
ubject to t
nly and s